an inner city teaching hospital. The diagnostic utility of post mortem lung culture was also evaluated. Design: A retrospective study was performed on all adult autopsies from July 2010 to July 2013 with fi nal histopathologic diagnosis of DAD. The histopathological features of DAD were re-evaluated by one autopsy pathologist and one pathology resident, based on the duration (exudative or proliferative phase), severity (bilateral/unilateral; focal/extensive) and pattern (classical vs. acute fi brinous and organizing pneumonia aka AFOP). Clinical history, pre and post mortem laboratory investigations, including postmortem lung culture (for bacteria, mycobacteria, fungi and virus) were reviewed to elucidate etiology. Results: 36 (16.2 %) cases showed histopathologic features of DAD out of 222 adult autopsies in the three year study period. Clinical ARDS was documented in 20 of these cases (55.6 %). DAD was interpreted as the immediate cause of death in 19 cases (8.6 %) and described as bilateral and extensive distribution in 75 % of cases. Morphologically, exudative phase and proliferative phase were found in 11 and 23 cases, respectively. AFOP pattern was identifi ed in 2 cases. Infection (28 cases and 77.8 %) was the most common etiology for DAD (bacterial-10, fungal-4, viral-3, parasitic-1, undetermined-10). 6 patients had history of chronic interstitial lung disease with superimposed acute infection. Other causes included malignancy (3 cases) and chemotherapy related (1 case). Interestingly, even after exhaustive tissue cultures and medical record review, 4 cases (11.1 %) did not show any obvious cause of acute lung injury, raising the possibility of acute interstitial pneumonia (AIP). Post-mortem lung cultures were performed in 16 cases of which 9 cases (56.3%) were positive (5 bacterial, 2 fungal and 2 viral infections). Conclusions: Our study highlights the morphological spectrum of DAD encountered in adult hospital autopsy in an inner city teaching hospital, infection being the most common triggering factor, especially during acute exacerbation of chronic interstitial lung disease. A signifi cant subpopulation of the cases had acute interstitial pneumonia, with no etiology identifi ed. Post-mortem lung culture was a valuable diagnostic tool. Background: Giant cell reparative granulomas (GCRG) are lytic lesions of the bone that predominantly occur in the gnathic bones but have also been described in the small bones of the hands and feet. Morphologically, they are indistinguishable from the so-called 'solid variant' of Aneurysmal Bone Cysts (ABC) in extra-gnathic sites. The neoplastic nature of primary ABCs has been established with the identifi cation of USP6 rearrangement in 70% of the cases. USP6 genetic alterations in giant-cell rich lesions (GCRG / ABC) of the small bones of the hands and feet has not been previously studied. Design: We investigated a group of 8 giant-cell rich lesions of the hands and feet by FISH for USP6 gene rearrangement, and further, compared the fi ndings with other morphologically similar lesions including 9 gnathic GCRGs, 22 primary ABCs, 8 giant cell tumors of bone and 2 brown tumors of hyperparathyroidism. Results: Overall, there were 49 samples from 48 patients including 26 females and 22 males. Radiologic imaging of the 8 lesions of the hands and feet showed 2 purely cystic, 1 purely solid and 4 mixed cystic and solid lesions. FISH for USP6 was performed on all of the 49 lesions in the study. Seven of the 8 (88%) lesions of the hand and feet showed rearrangement of the USP6 gene. No USP6 gene rearrangements were identifi ed in the 9 cases of gnathic GCRGs, 2 cases of brown tumor or the 8 cases of GCT of bone. Thirteen of the 22 (59%) primary ABCs from the long bones and fl at bones showed rearrangements of the USP6 gene rearrangement. Conclusions: Our results suggest that the majority of the GCRGs of the hands and feet represent true ABCs and should be reclassifi ed as such. The terminology of GCRG should be restricted only to lesions in the gnathic location. FISH for USP6 is a useful ancillary tool in the diagnosis of primary ABCs, and can be extremely helpful in distinguishing them from GCRGs and other morphologically similar lesions. Morphology NP Agaram, L Zhang, Y-S Sung, S Singer, CR Antonescu. Memorial Sloan-Kettering Cancer Center, New York, NY. Background: Extraskeletal myxoid chondrosarcoma (EMC) is a rare soft tissue sarcoma with distinctive histology and uncertain histogenesis, characterized by EWSR1-NR4A3 fusion in 75% of the cases. A smaller proportion of cases show NR4A3 fused to other gene partners including TAF15, TCF12 and TFG. The impact of various gene fusions on morphology and outcome has not been previously evaluated. Design: We investigated a group of 26 consecutive EMCs with adequate material for FISH and/or RT-PCR analysis and correlated the genetic fi ndings with morphology and clinical outcome. Results: There were 5 females and 21 males, with a median age of 49.5 years. The mean size of the tumors was 11.1 cm. FISH analysis showed that 16 (62%) of the 26 cases had the EWSR1-NR4A3 gene fusion, 7 (27%) cases showed TAF15-NR4A3 gene fusion and 1 (4%) case showed TCF12-NR4A3 gene fusion. No rearrangements of the TFG or FUS genes were identifi ed. Upon correlation, the morphology of most EWSR1-rearranged tumors (10 of 16) showed low cellularity, minimal cytologic atypia and low mitotic counts. In contrast, a predominant number of cases (80%) with variant (non-EWSR1) NR4A3 gene fusions (TAF15, TCF12) showed distinctive plasmacytoid / rhabdoid morphology, with increased cellularity, cytologic atypia and high mitotic counts. Follow-up showed that only 1 of 16 patients with EWSR1-rearranged tumors died of disease, in contrast to 3 of 7 (43%) patients with TAF15-rearranged tumors. Conclusions: In conclusion, EMCs with variant NR4A3 gene fusions show a higher incidence of rhabdoid phenotype, high grade morphology and a more aggressive outcome compared to the more common EWSR1-NR4A3 positive tumors. Furthermore, as EWSR1 FISH break-apart assay is the preferred ancillary test to confi rm diagnosis of EMC, tumors with variant NR4A3 gene fusions remain under-recognized and often misdiagnosed. FISH assay for NR4A3 rearrangements recognizes >95% of EMCs and should be an additional tool in EWSR1-negative tumors.
(non-EWSR1) NR4A3 gene fusions (TAF15, TCF12) showed distinctive plasmacytoid / rhabdoid morphology, with increased cellularity, cytologic atypia and high mitotic counts. Follow-up showed that only 1 of 16 patients with EWSR1-rearranged tumors died of disease, in contrast to 3 of 7 (43%) patients with TAF15-rearranged tumors. Conclusions: In conclusion, EMCs with variant NR4A3 gene fusions show a higher incidence of rhabdoid phenotype, high grade morphology and a more aggressive outcome compared to the more common EWSR1-NR4A3 positive tumors. Furthermore, as EWSR1 FISH break-apart assay is the preferred ancillary test to confi rm diagnosis of EMC, tumors with variant NR4A3 gene fusions remain under-recognized and often misdiagnosed. FISH assay for NR4A3 rearrangements recognizes >95% of EMCs and should be an additional tool in EWSR1-negative tumors.
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Solitary Fibrous Tumor "Hemangiopericytoma" of Skin Is Rare; Other Differentials Should Be Considered OI Ahmed, A AlSayyah, SS Qasem. Wake Forest School of Medicine, Winston Salem, NC. Background: Solitary fi brous tumor (SFT), formerly hemangiopericytoma (HPC), is a rare neoplasm that can arise anywhere in the body. The majority of cases are benign; however, it can be of borderline or frank malignancy. Histologically it's composed of fi broblast-like spindled cells with variable cellularity, intervening collagen bundles and staghorn-like vasculature. Although the majority of SFT arise in the deep soft tissue, and body cavities, they can also be located superfi cially. In fact, they are frequently considered in the differential diagnosis of spindle cell lesions with prominent vasculature in the skin and subcutaneous tissue. The goal of this project is to study the frequency of SFT in skin. Design: We searched our database for cases diagnosed as SFT or HPC. We then classifi ed cases into superfi cial and deep based on the clinical information and the pathology report. The slides of all potential superfi cial cases were pulled and evaluated microscopically for the presence of skin in the specimen, the location of the tumor in relation to the skin and the histomorphology of the lesion. Any associated immunostains were also evaluated. Results: Our search retrieved 134 specimens, belonging to 108 patients, examined in our hospital over the course of 36 years. The specimens included 2 autopsies, 5 cytology specimens and 127 surgicals (biopsies and resections). 68% of the cases were considered benign, 4% were borderline and 28% were malignant. 81% percent were primary, 8% were recurrent and 11% were metastatic. The majority (87%) were deep and only 13% were potentially superfi cial. Of the superfi cial cases, only 4 cases were involving or intimately associated with skin; 2 of which showed metastatic SFT from other deep preidentifi ed primary sites; the other 2 were not morphologically conclusive for SFT (one is believed to be nodular fasciitis and the other is an aneurysmal fi brous histiocytoma). However, it has been unclear whether these trends have remained constant over time. The aim of the study was to examine the frequencies of primary tumors among all patients with bone metastases over the last 3+ decades. Design: The tumor registry of the authors' institution was searched to identify cases of BM. The clinicopathological characteristics were recorded. Hematologic malignancies and soft tissue sarcomas directly involving bone were excluded. The remaining cases were divided into decades and further separated by gender.  2 test was utilized for statistical analysis. Results: There were 2,355 cases identifi ed by our inclusion criteria. LC was the most frequent primary tumor in men across all decades, followed by PC (ranged 45-50% vs. 18-23%; P<.0001). While BC and LC showed similar frequencies in women in the 1980's (33% and 32%, respectively), lung surpassed breast as the primary tumor site by approximately 10% thereafter in each decade (37-41% vs. 26-34%, P=.03). The other most common tumors included RCC, head/neck (HN; excluding thyroid) and gastrointestinal carcinomas in men; and those of HN, RCC and gynecologic origins in women, accounting for about 15% in each gender. No tumor type showed a signifi cant variation in frequency over the study period. Tumors of unknown primary (TUP) dropped signifi cantly from 14% (1980's) to 7% (1990's) to 0.6% (2000 and thereafter; P<0.001), with no difference between genders. Not surprisingly, PC showed the highest tendency to relapse in bone on the fi rst metastasis (95%), followed by HN (93%), LC (82%), BC (79%) and RCC (71%).
Conclusions:
The trends in primary tumor metastasizing to bone have remained consistent over the last few decades. Given that PC and BC are by far the most prevalent malignancies in men and women, respectively, LC represents the highest number of metastatic bone disease cases relative to its incidence. These changes may represent locoregional predisposing factors to LC or later detection when compared to PC and BC. The signifi cant drop in TUP refl ects the recent advancement in immunohistochemistry and molecular genetic techniques.
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GIST Associated with Desmoid Fibromatosis M Caragea, D Stockman, K Torres, A Lazar, J Meis. MD Anderson Cancer Center, Houston, TX. Background: Gastrointestinal stromal tumors (GIST) may be associated with other neoplasms (carcinoma, lymphoma, leukemia) as either a preceding or synchronous malignancy. The association of GIST and mesenchymal neoplasms is relatively rare (neurofi broma, liposarcoma and leiomyosarcoma). We report 8 patients with GIST who also had desmoid fi bromatosis in close anatomic proximity. Design: Patients with GIST associated with desmoid fi bromatosis were retrieved from the fi les of a major referral center. Morphologic, immunohistochemical, sequencing, and outcome data were analyzed. Results: Eight patients with desmoid fi bromatosis and GIST were identifi ed. All tumors occurred within the abdominal cavity. Median patient age was 59 years with males predominating (6/8). GIST occurred prior to the development of desmoid in 6 patients and at the site of the prior surgical resection in 3. In one patient the tumors were synchronous and in one the desmoid preceded GIST. Median interval to the development of the 2 nd tumor was 36 mos. Most GIST occurred in the stomach (5), followed by small bowel (2) and omentum (1). Median GIST size was 7.5 cm. Six GIST were categorized as moderate to high risk and 2 as low risk. KIT and/or PDGFRA mutation analyses (5) revealed point mutations or deletions in exon 11 of the KIT gene. Desmoids ranged from 1.5 -8.5 cm and were located in gastric and perigastric soft tissue (3), small bowel (2), colon (1) and abdominal wall (1). Mutations were detected in exon 3 of the CTNNB1 gene (5). Clinical follow-up in 7 patients revealed 5 were alive and disease free and 2 were alive with disease (one with desmoid and one with GIST). Two patients with GIST developed recurrences and one hepatic metastasis.
Conclusions:
The occurrence of GIST with desmoid fi bromatosis does not appear to be fortuitous based on the cases in this series and the small number of reported cases. Notably, all cases of GIST in this series were intra-abdominal as were the desmoids, with nearly 40% of desmoids occurring at the site of a GIST that had been surgically removed. No relationship was found between the specifi c mutations seen in the GISTs or desmoids. A recurrent mass at the site of a previous GIST should not be assumed to be GIST clinically and vice versa. Histologic confirmation with appropriate immunohistochemical and molecular studies is strongly recommended in such cases.
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Atypical Neurofibromata Do Not Display Malignant Behavior Despite Concerning Histologic Features M Caragea, A Lazar, W-L Wang. MD Anderson Cancer Center, Houston, TX. Background: Atypical neurofi bromata are usually seen in the setting of neurofi bromatosis. They can be clinically and histiologically concerning with increased cellularity, scattered atypia and rare mitotic activity. While the criteria for diagnosis are not well established, there are certain peripheral nerve sheath tumors that warrant such diagnosis. We assessed the clinical behavior and outcome of these lesions at our institution. Design: Twenty-four cases (20 patients) were retrieved from pathology archives. Available clinical data and tumor properties were tabulated. The tumors were evaluated for the following: growth pattern, cellularity, cytologic atypia, mitotic count and necrosis. Immunohistochemistry for S100 protein, P53 and Ki-67 were performed. Results: The median age was 21 years-old (range: 15 and 68) with equal male:female ratio. Tumors arose primarily in the setting of neurofi bromatosis type 1 (14/24) or in association with nerves (6/24). Most involved the trunk and extremities with a median size of 5.5 (range: 1.1 to 9.5) cm. Most patients presented with enlarging mass sometimes with compressive symptoms, such as pain or numbness, or in the setting of known neurofi bromatosis complicated by PET avid tumors (20/24). Surgical resection was performed in 22/24 cases. Microscopically, all tumors were composed of spindle cells with wavy nuclei with a classic neurofi bromatous growth pattern, some with myxoid stroma. The punctuated cytologic atypia was scattered throughout the neoplasm, ranging from moderate to scattered highly atypical nuclei (n=21). Most (n=14) showed 1-2 mitoses/10 HPF. Necrosis was not identifi ed. S-100 protein was performed in 12/24 cases and was diffusely and strongly expressed in all, while P53 was negative or weakly expressed in 10/24 cases (5-40% of tumor nuclei). Ki-67 marked <1-30% of tumor nuclei. Of patient with follow-up (n=16), one progressed to MPNST in the same location one year after excision. Most patients are alive (12), disease free or living with disease. Four patients died, three of unknown cause (but not related to aggressive tumor behavior) and one due to surgical complications. Conclusions: Atypical neurofi bromas represent a subset of peripheral nerve sheath tumors seen primarily in the setting of neurofi bromatosis. Despite their concerning cytologic and architectural features, these tumors behave in a benign fashion and should be distinguished from MPNST. Progression to MPNST appears to be rare. S100 protein is diffusely expressed in atypical neurofi bromas and is helpful in this differential diagnosis.
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Malignant Peripheral Nerve Sheath Tumor (MPNST) with Low Grade Histologic Features Is a Fully Malignant Neoplasm with Aggressive Behavior M Caragea, A Lazar, W-L Wang. MD Anderson Cancer Center, Houston, TX. Background: MPNST with low grade histologic features is controversial with some doubting the utility of histologic grading. However, some neurogenic sarcomas with increased cellularity and mitotic activity lack the overt atypia and necrosis seen in most conventional MPNST. We examined a cohort of patients with tumors which fall within the spectrum of MPNST but with low-grade histology. Design: Cases were obtained from our pathology archives. Association with large nerves or neurofi bromatosis was noted. Criteria used for diagnosis include: increased cellularity, fascicular growth, uniform cellular histology with relatively mild atypia, mitotic activity, and patchy S100 protein expression. Clinical data and tumor properties were tabulated. The tumors were evaluated for: growth pattern, cellularity, cytologic atypia, mitotic count and necrosis. A panel of immunohistochemical markers, including S-100 protein, p53 and Ki-67 was performed. Results: Eight cases were retrieved. Majority were sporadic (6/8) while 2 patients had NF1. The median age was 40 (range 16 -64) years-old. Majority of patients were females (5/8). Most presented with an enlarging mass and involved the upper extremity and head and neck neural plexus. Median tumor size was 7 cm (range 1.2 to 9.5) cm. Most tumors (5/8) displayed a fascicular growth pattern with fi brous bands separating nodules with a vague alternating hypo-and hypercellular areas and sometimes peripheral condensation. A myxoid background was appreciated in some tumors. The neoplastic cells were monotonous, spindled to more rounded, with relatively mild atypia. Median mitotic activity 3/10 hpf (range: 1 to 10 mitoses per 10 high power fi elds). Necrosis was not identifi ed. 5/8 cases had patchy labeling for S-100 protein. Weak nuclear P53 was expressed in 3/4 case and strong in 1(range, 15-80% of nuclei). The Ki-67 proliferative index was low, with median of 5% (range<1%-30%). Seven patients had follow up with a median follow up time of 2 years (range 1-6 years). Local recurrence was seen in 50% (4/8) of the patients, while metastases were documented in one case. Four patients succumbed: 2 with disease (median time to death 3 years) and two of unknown causes. One patient is well with no evidence of disease. Conclusions: Neurogenic sarcomas can have distinctive low-grade morphology that is different from atypical neurofi bromas and classical high grade MPNST, and most are sporadic. Despite their low grade histologic features, are aggressive neoplasms with high rates of local recurrence and metastatic capacity.
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Atypical Notochordal Cell Tumors: A Clinicopathologic Review of "Unclassifiable" Notochordal Tumors JM Carter, DE Wenger, CY Inwards. Mayo Clinic, Rochester, MN. Background: By current WHO classifi cation, notochordal-derived tumors include benign notocordal cell tumor (BNCT) and chordoma, a malignant tumor with locally aggressive behavior. Defi ned radiologic and histologic criteria distinguish them. For example, BNCTs do not show radiologic evidence of bone destruction or extra-osseous extension. This distinction is essential as chordomas warrant aggressive surgical management while BNCT can be followed with serial imaging. We report our experience with a subset of BNCTs with atypical features and propose an alternative category of atypical notochordal cell tumors. Design: Three cases of BNCTs with unusual radiologic features were retrieved from our archives. Radiologic re-review was performed to assess cortical and soft tissue involvement. Histologic re-review was performed. Immunohistochemistry for cytokeratins and brachyury was performed. Results: Case 1 (52 y, male): MRI showed a 2.1cm sacral (S4) lesion showing features of BNCT with the exception of cortical breakthrough with minimal soft tissue extension. Following complete resection, histologically, the tumor (in toto) showed typical features of BNCT. At 36 mos follow-up, there is no evidence of recurrent disease. Case 2 (60 y, male): MRI demonstrated a lumbar (L4) spine lesion showing radiologic features of BNCT with the exception of a minimal (6.0 mm) extradural soft tissue mass. Histologically, the biopsy tissue was BNCT. Re-biopsy at 6 yrs showed histologic features of BNCT with very focal myxoid change and tumor cell cording. However, serial imaging (total 8 yrs) has shown < 2mm interval growth of the soft tissue component. He continues to be followed with serial imaging. Case 3 (74 y, male): MRI demonstrated a sacral mass (S3) showing features of BNCT with the exception of cortical breakthrough posteriorly and minimal extension into the sacral canal. Histologically, the biopsy tissue was BNCT. To date (8 mos), there is no evidence of tumor progression. In all cases, the tumors expressed cytokeratins and brachyury.
Cox regression analysis of recurrence-free survival.
Hazard Limiting Cox regression models to samples meeting increasingly stringent thresholds for predicted probability of positive SRM or by number of sections evaluating SRM had no effect on the hazard ratios for SRM status.
Conclusions:
Resection margins fail to predict RFS for DTF. The number of positive SRM, linear extent of margin involvement and tissue composition also fail to predict RFS. However, decreasing clearance appears to be predictive of recurrence in cases with negative SRM. Although the optimum number of tissue sections for evaluation of SRM is unclear, most cases appear to be adequately sampled. AL Cheah, SD Billings, JR Goldblum, P Carver, M Tanas, BP Rubin. Cleveland Clinic, Cleveland, OH. Background: Recurrent NAB2-STAT6 gene fusions have recently been identifi ed in solitary fi brous tumors (SFT) by integrative sequencing. Nuclear expression of STAT6 by immunohistochemistry (IHC) discriminates meningeal SFT from its mimics in the central nervous system. Our aim was to examine the sensitivity and specifi city of STAT6 IHC for SFT versus other morphologically similar soft tissue tumors. Design: STAT6 expression was evaluated by IHC in 53 SFT of various sites and 99 soft tissue tumors in the histologic differential diagnosis. We used two antibodies (Epitomics and Santa Cruz) using FFPE whole sections and tissue microarray slides. Only nuclear staining of STAT6 was considered positive. Staining was scored as: 0 (no staining), 1+ (1-25%), 2+ (26-50%), 3+ (>50%). Intensity was scored as weak, moderate or strong.
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STAT6 Is a Sensitive and Specific Marker of Solitary Fibrous Tumor
Results: Our preliminary workup of the STAT6 Santa Cruz antibody showed excessive noise to signal ratio, which precluded accurate scoring. Thus, we elected to focus on the STAT6 Epitomics rabbit monoclonal antibody (1:100), which has not previously been examined by others, in our expanded study. Nuclear STAT6 staining was present in all SFT cases tested (53/53, sensitivity 100%). The majority of cases showed 3+ and strong intensity staining. All tested cases of cellular angiofi broma (0/9), myofi broblastoma (0/10), spindle cell lipoma (0/10), benign fi brous histiocytoma (0/13), dermatofi brosarcoma protuberans (0/9), low-grade fi bromyxoid sarcoma (0/7), schwannoma (0/8), desmoid fi bromatosis (0/8), monophasic synovial sarcoma (0/11), malignant peripheral nerve sheath tumor (0/7), and mesenchymal chondrosarcoma (0/7) were negative for STAT6 (specifi city 100%). Conclusions: Our study provides further support that STAT6 is an extremely sensitive and specifi c marker for SFT and is a useful diagnostic adjunct in discriminating SFT from other soft tissue tumor mimics.
46
Expression of Growth-Associated Protein 43 (GAP43) in Malignant Peripheral Nerve Sheath Tumors Arising in the Neurofibromatosis-1 and Sporadic Settings W-S Chen, P-L Chen, LP Dehner. Washington University in St. Louis, Saint Louis, MO; MD Anderson Cancer Center, Houston, TX. Background: The malignant peripheral nerve sheath tumor (MPNST) is a relatively uncommon type of soft tissue sarcoma arising from a peripheral nerve or extraneural soft tissues and showing nerve sheath differentiation. The diagnosis of MPNST can be one of the more challenging tasks due to its uncommon type, morphologic resemblance to other spindle cell neoplasms and lack of sensitive and specifi c immunohistochemical markers. The diagnosis is more straightforward in the clinical setting of neurofi bromatosis-1 (NF-1), but problems are mainly centered on the sporadic (non-NF-1) MPNSTs. We recently reported the utility of a novel marker, Growth-associated protein 43 (GAP43), a membrane-associated phosphoprotein expressed in neuronal growth cones and Schwann cell precursors during neural development and axonal regeneration, in differentiating a set of benign and malignant nerve sheath tumors from other non-nerve sheath spindle cell neoplasms. We also showed that, in the setting of NF-1, GAP-43 has a sensitivity (86%) superior to S100 protein (62%). Here, we expanded our study to include a series of 19 sporadic (non-NF-1) MPNSTs. Design: A series of 19 sporadic MPNSTs were selected from our surgical pathology archives, including 3 biopsies and 16 resection specimens. All cases showed at least positivity for one of the following three markers, namely S100 protein, collagen IV and Leu7. Immunohistochemical staining using anti-GAP43 and anti-S100 protein antibodies was performed on consecutive sections for each case. Results: In this study, we showed that GAP43 is positive in 8/19 cases (42%), a result comparable to S100 protein (n= 10/19; 52%). (Table 1 .) Table 1 . S100 protein and GAP43 expression in sporadic MPNSTs Neg Pos 0-5% 25-50% >50% S100 9 1 0 5 3 2 GAP-43 1 0 9 6 2 1
Conclusions: Even though GAP43 is a highly sensitive marker and superior to S100 protein for the diagnosis of MPNSTs in the NF-1 setting, the utility of this marker in the sporadic MPNSTs is more limited, and awareness of this caveat is important. Both comparative genomic hybridization studies and studies analyzing germline and somatic NF1 mutations suggest that the NF-1 and sporadic MPNSTs harbor different genetic changes, which may be refl ected in part in the expression of GAP43. Our data provide further evidence that the MPNSTs arising from these two settings may refl ect two different pathogenetic mechanisms. S-J Cho, M Doral, A Sabnis, ML Loh, M Applebaum, SG Dubois, AE Horvai . UCSF, San Francisco, CA. Background: Ewing sarcoma (ES) is a rare malignant small round blue cell tumor (SRBCT) characterized by chromosomal translocations resulting in fusions involving the EWSR1 gene. SRBCT that morphologically and clinically fi t a diagnosis of ES but lack EWSR1 rearrangement pose a diagnostic dilemma. A subset of such ES-like sarcomas demonstrates fusion between the BCOR and CCNB3 genes (encoding the BCL6 corepressor and cyclin B3, respectively). Preliminary results suggest that these ES-like sarcomas may be detected by immunohistochemistry for CCNB3 protein. However, the diagnostic utility of CCNB3 immunohistochemistry in a large group of genetically characterized SRBCT has not been tested. We investigated the specifi city of CCNB3 immunohistochemistry in SRBCT. Design: We studied 48 SRBCT, previously characterized for EWSR1 rearrangement. The SRBCT subtypes included conventional ES (classic clinicopathologic features of ES with EWSR1 rearrangement, n=38), ES-like sarcoma (classic clinicopathologic features of ES but absent EWSR1 rearrangement, n=3), unclassifi ed SRBCT (indeterminate EWSR1 rearrangement status, n=5) and other EWSR1-associated SRBCT (desmoplastic small round cell tumor and clear cell sarcoma, n=2). Formalin fi xed-paraffi n embedded tissue was stained using a combination of duplicate tissue microarrays, whole sections, or both using the CCNB3 polyclonal antibody HPA000496. Immunostaining for CCNB3 and detection of BCOR-CCNB3 fusion by RTPCR was performed as previously reported (Pierron et al. Nat Genet. 2012; 44:461-468) . Strong cytoplasmic and/or nuclear staining was considered positive. Results: Immunohistochemical staining results for CCNB3 are summarized in Table  1 . Only one SRBCT (1/48, 2%) showed CCNB3 staining, which was cytoplasmic. RTPCR and DNA sequencing demonstrated a BCOR exon 15 to CCNB3 exon 5 fusion in this tumor. Background: In contrast with the classifi cation of soft tissue spindle/pleomorphic sarcomas, the classifi cation of the much rarer spindle/pleomorphic sarcomas of bone is still limited to few entities as fi brosarcoma, undifferentiated pleomorphic sarcoma (formerly MFH), and leiomyosarcoma. Design: 430 cases diagnosed as primary spindle/pleomorphic sarcomas of bone for the period 1937-2012 were retrieved from our archives. Thirty cases were excluded for the lack of material. Clinical records, pathology and radiology reports were reviewed. Secondary spindle/pleomorphic sarcomas of bone, cases without adequate slides, and spindle/pleomorphic sarcomas secondarily involving bone were excluded. Immunohistochemistry for cytokeratins AE1/AE3, SMA, desmin, S-100, CD34, MDM2, CD99, EMA, caldesmon, myogenin, TLE1, ALK, ERG, CD31, neurofi lament, GFAP, vimentin and Bcl-2 was performed using commercial antibodies. EWSR1 and SYT gene rearrangements detected by FISH were performed when relevant. In all cases long term follow-up was available. Results: On the basis of the histologic, clinico-radiological, immunohistochemistry and molecular review, of the 400 study cases, 326 were confi rmed as primary spindle/ pleomorphic sarcomas of bone. Following reclassifi cation fi brosarcomas dropped from 128 to 9; undifferentiated pleomorphic sarcoma from 141 to 47; malignant peripheral nerve sheath tumor from 10 to 8 and hemangiopericytoma from 10 to none. Leiomyosarcoma raised from 33 to 142; myoepithelioma from 2 to 12, and of synovial sarcoma from 1 to 25. In addition other distinct entities were recognized as primary tumors of bone: myofi broblastic sarcoma (49 cases), solitary fi brous tumor (22 cases), mixofi brosarcoma (7 cases), pleomorphic rhabdomyiosarcoma (3 cases), pleomorphic liposarcoma (1 case) and pseudomiogenic hemangioendothelioma (1 case). Survival curves showed signifi cant correlation with the revised subclassifi cation. Conclusions: Using strict diagnostic criteria and immunohistochemical and molecular analysis, commonly used diagnostic entities (fi brosarcoma, undifferentiated pleomorphic sarcoma/MFH and hemangiopericytoma ) tends to disappear whereas distinct entities tends to emerge. When primary spindle cell/pleomorphic sarcomas of bone are accurately sublassifi ed, histoype appears as a signifi cant predictor of outcome. EG Demicco, PW Harms, RM Patel, SC Smith, SL Carskadon, S Camelo-Piragua, JB McHugh, J Siddiqui, N Palanisamy, DR Lucas, AJ Lazar, W-L Wang. Mount Sinai Medical Center, New York, NY; University of Michigan Medical Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX. Background: Solitary fi brous tumors (SFT) are rare mesenchymal tumors that can be challenging to diagnose, especially in small biopsies, meningeal tumors and those tumors with anaplasia. Recently, SFTs have been discovered to harbor a recurrent gene fusion involving NAB2 and STAT6, resulting in overexpression of STAT6. We assessed the diagnostic utility of nuclear expression of STAT6 in identifying SFT, and inquired if STAT6 might also play a role in other mesenchymal neoplasms. Design: Tissue microarrays and tissue sections of a variety of mesenchymal tumors (see Table 1 ) were stained for STAT6 (1:200; M-20, SC-981, Santa Cruz), using an automated immunohistochemical stainer (Ventana). Nuclear and cytoplasmic staining were scored as 0 (absent-minimal blush), 1 (weak), 2 (moderate), or 3 (strong). Only 2-3+ nuclear stain was considered positive. Results: Of the 1419 cases assessed (Table 1) , nuclear STAT6 was 2-3+ in 240 cases (17%), including 202/250 SFT (81%), 6/55 (11%) unclassifi ed sarcomas, 16/184 (9%) desmoids, 4/63 (7%) neurofi bromata, and 3/154 (2%) undifferentiated pleomorphic sarcomas. When present, STAT6 nuclear stain was seen diffusely in a majority of tumor cells. Amongst non-neoplastic tissues, scar was positive in 6/17 (35%). Nearly 1/3 of meningeal and intraabdominal tumors were negative for STAT6, compared to less than 10% of pleural tumors. Conclusions: STAT6 immunohistochemistry is a relatively sensitive and specifi c test for SFT. Although occasionally moderate nuclear staining may be seen in other proliferations including unclassifi ed sarcomas, neurofi bromas, desmoids and scars, the role of STAT6 in these tumors is yet to be determined. Correlation with RT-PCR studies for NAB2-STAT6 fusion are ongoing. Alveolar soft part sarcoma  0  25  0  Angiosarcoma  0  67  0  Clear cell sarcoma  1  19  5  Dermatofi brosarcoma protuberans +/-fi brosarcomatous transformation  0  6  0   Desmoid  16  184  9  Epithelioid sarcoma  1  31  3  Fibrosarcoma  0  3  0  Gastrointestinal stromal tumor  1  26  4  Leiomyoma  0  15  0  Leiomyosarcoma  2  366  1  Liposarcoma  1  16  6  Low grade fi bromyxoid sarcoma  0  5  0  Malignant peripheral nerve sheath tumor  2  111  2  Neurofi broma  4  59  7  Sinonasal glomangiopericytoma  0  3  0  Solitary fi brous tumor  202  250  81  Synovial sarcoma  1  24  0  Unclassifi ed sarcoma  6  55  11  Undifferentiated pleomorphic sarcoma  3  154  2  Total  240  1419 Background: Perineuriomas are uncommon soft tissue tumors showing exclusively perineurial differentiation. Most perineurial tumors are histologically banal and behave in a benign fashion. However, rare perineurial tumors show atypical morphological features and behave aggressively; some of these tumors have been reported as perineurial malignant peripheral nerve sheath tumors . We studied a large series of perineurial tumors to better understand the natural history of these rare lesions, and better defi ne criteria for malignancy in perineurial tumors. Design: 46 cases previously coded as showing exclusively perineurial differentiation were retrieved. Cases were re-reviewed with attention to morphology (growth pattern, cellularity, mitotic rate, nuclear pleomorphism, and necrosis), and immunophenotype (EMA, GLUT1, claudin-1, CD34, and collagen IV). By defi nition, S100 protein expression was absent. Follow-up information was obtained.
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CCNB3 Immunohistochemistry Is Highly Specific for BCOR-CCNB3 Fusion Sarcomas
49
STAT6 Immunohistochemistry Is Useful in the Diagnosis of Solitary Fibrous Tumors
Results:
The tumors occurred in 19M and 27 F (median age 42 yrs.; range 12-78 yrs.) and ranged from 0.9-14cm (median 3.5 cm) in size. Common sites of occurrence included the extremities and trunk; the head/neck and viscera were rarely involved. Growth patterns, when evaluable, were circumscribed (15) and infi ltrative (20). Nuclear grade was low (16), intermediate (18) and high (12). Cellularity was low (30), intermediate (11) and high (5). Necrosis was present in only 3 cases. Mitotic count was 0-100 mitotic fi gures/ 50 HPF (median 1/50 HPF). IHC results: EMA (46/46, only focal staining in 11/46), claudin-1 (30/43), GLUT-1 (35/42), CD34 (14/18), collagen IV (9/9). Clinical follow-up of >10 mos. was available for 10 patients (median 41 mos., range 10-216 mos.); 8 were alive without disease, 1 alive with disease and 1 dead of disease. Local recurrences occurred in 2 cases and metastases in 1 case. Local recurrences and metastases occurred only in tumors showing atypical features (e.g., high nuclear grade or cellularity, necrosis, mitotic count >1/50HPF). Conclusions: A combination of careful morphological study and ancillary IHC should allow for the confi dent diagnosis of perineurial tumors, including those with atypical or worrisome morphological features. Preliminary follow-up data suggests that perineurial tumors lacking atypical morphological features behave in a clinically benign fashion, with adverse events occurring only in morphologically atypical tumors.
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Genomic Analysis of 423 Sarcomas: A Single Institution Experience LA Doyle, VY Jo, JL Hornick, CP Raut, LM Sholl, NI Lindeman, CDM Fletcher, AJ Wagner. Brigham and Women's Hospital and Harvard Medical School, Dana Farber Cancer Institute, Boston, MA. Background: Genomic analysis of tumors is becoming increasingly available, but the spectrum of abnormalities across large tumor sets is not well established. This study aimed to identify the frequency and types of genomic alterations detected in sarcomas using mutation hotspot-based analysis (OncoMap), and a more recent targeted exome sequencing platform (OncoPanel). Design: FFPE tissue from 423 sarcomas was analyzed. OncoMap detects 472 mutations in 41 cancer-related genes by targeted multiplex PCR amplifi cation and mass spectrometry analysis. OncoPanel surveys exonic DNA sequences of 275 cancerrelated genes and 91 introns across 30 genes for rearrangement by massively parallel sequencing using an Illumina HiSeq 2500 sequencer. MuTect and GATK were used to detect single nucleotide variants and indels, and VisCap to detect copy number variation. Results: OncoMap detected missense mutations in known cancer-related genes in 83 (21%) of 398 samples. OncoPanel detected 158 missense mutations in 25 samples: of these 20 are known to be clinically signifi cant or have known tumorigenic function and 138 were of unknown signifi cance. As expected, OncoPanel had greater sensitivity in detection of missense mutations than allele-specifi c analysis; e.g., Oncomap detected 3 mutations in 27 dedifferentiated liposarcomas (DDLPS): Oncopanel detected 50 mutations in 7 DDLPS. Expected fi ndings included KIT and PDGFRA mutations in GIST, CTNNB1 mutations in desmoid fi bromatosis and TP53 mutations in pleomorphic liposarcoma. CTNNB1 mutations were also found in synovial sarcoma, MPNST and DDLPS. PI3K pathway (PIK3CA, AKT, MTOR) mutations were confi rmed in myxoid liposarcoma and RAS mutations in angiosarcoma. Promising fi ndings included KRAS  PIK3CA mutations in GIST, KRAS  PTEN mutations in leiomyosarcoma, and PIK3CA  TSC2 mutations in osteosarcoma. TP53 mutations were present in many different sarcoma types including some Ewing sarcomas. Mutations of uncertain signifi cance involved the ARID family in various sarcoma types and DICER in leiomyosarcoma. High copy number gains were frequent in DDLPS. Low copy number gains and single gene deletions were frequent across various sarcoma types. Targeted validation of these fi ndings in a larger panel of tumors is underway. Conclusions: Given the wide spectrum of sarcoma types, a broad screening platform allows for greater detection of genomic events. Although the therapeutic and prognostic signifi cance of the reported fi ndings in most sarcoma types, other than GIST, remains to be determined, such data may help match clinical trials to the appropriate genotype.
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STAT6 Is Amplified in a Subset of Dedifferentiated Liposarcoma LA Doyle, DL Tao, A Marino-Enriquez. Brigham and Women's Hospital and Harvard Medical School, Boston. Background: STAT6 is a member of the STAT family of cytoplasmic transcription factors. Recent studies have detected a recurrent intrachromosomal rearrangement in solitary fi brous tumor that results in the formation of a NAB2-STAT6 fusion oncogene. Nuclear expression of STAT6 by immunohistochemistry (IHC) is found in nearly all cases of SFT and serves as a useful diagnostic marker. STAT6 is located in 12q13, a chromosomal region containing well-characterized oncogenes that are commonly amplifi ed in dedifferentiated liposarcoma (DDLPS), and expression of STAT6 has been reported to occur in a subset of DDLPS. The aim of this study was to determine the frequency of STAT6 expression and the underlying genetic mechanism in DDLPS. Design: STAT6 protein expression was evaluated in whole tissue sections from a wellcharacterized series of 35 DDLPS, all with nuclear MDM2 and CDK4 expression by IHC and/or cytogenetic features of DDLPS. IHC was performed following pressure cooker antigen retrieval (0.01 M citrate buffer, pH 6.0) using a rabbit polyclonal STAT6 antibody (1:1000; sc-621; Santa Cruz Biotechnology, Santa Cruz, CA). Dual color FISH was performed with a commercial probe targeting the 12q13 region, which includes a SpectrumOrange probe spanning the STAT6 locus and a telomeric SpectrumGreen probe (Vysis, Abbott Molecular Inc, Des Plaines, IL), on 4-μm formalin-fi xed paraffi nembedded sections on all cases with STAT6 expression, and a subset of control cases without. 100 cells were scored per case. The presence of 5 or more orange signals was considered indicative of STAT6 amplifi cation. Non-neoplastic diploid cells were used as internal controls in each case. Results: 4/35 cases (11%) showed nuclear expression of STAT6 by IHC -3 with multifocal moderate to strong staining and 1 with weak focal staining-in either well-differentiated sclerosing or dedifferentiated components. FISH demonstrated amplifi cation of STAT6 in the 4 positive cases; in contrast, FISH demonstrated no STAT6 amplifi cation on 4 tumors negative for STAT6 expression by IHC. Of the 4 STAT6 amplifi ed cases, 3 patients were male and 1 female, ranging in age from 51 to 76 years. Tumors were located in the mediastinum (n=2), paratesticular soft tissue (1) and perirenal soft tissue (1). 3 patients received chemotherapy +/-radiation therapy prior to resection. Conclusions: STAT6 is amplifi ed in a subset of DDLPS, which leads to nuclear expression of STAT6 that can be detected by IHC. These fi ndings suggest a role for STAT6-mediated transcriptional activity in some cases of DDLPS, and highlight the genomic complexity and heterogeneity of DDLPS. Background: Nodular fasciitis (NF) and aneurysmal bone cyst (ABC) are mesenchymal tumors that predominantly occur in younger patients and exhibit overlapping histologic features. While ABC is primarily a bone neoplasm, nodular fasciitis is exclusively encountered in the soft tissues. Recent studies have shown that both tumors harbor USP6 fusion genes but with distinct 5'-end partner genes. In this study we describe a novel fusion of the pre-mRNA splicing factor gene SRSF3 (serine/arginine-rich splicing factor 3) to the ubiquitin protease USP6 in both NF and ABC. Design: One example each of ABC and NF were identifi ed with the same t(6;17) (p21;p13) by conventional cytogenetic analysis. Additional cases of NF (n=7) and ABC (n=6) that were previously shown to harbor USP6 rearrangement but without a known partner gene were also studied. Histologic diagnosis was confi rmed in all cases according to the 2013 WHO classifi cation. RNA was extracted from archival FFPE from both ABC and NF with t(6;17). cDNA libraries were prepared using RNA was prepared for transcriptome analysis by paired-end sequencing using the Sure Select RNA target enrichment for Illumina Paired-End Multiplexed Sequencing kit (Agilent Technologies, Englewood CO). Transcriptome sequencing analysis was performed using a HiSeq 2000 sequencer (Ilumina Inc, San Diego, CA). SnowShoes-FTD algorithm for paired end mRNA-Seq data was used to identify any potential fusion gene (Asmann Y et al., 2011) . Break-apart FISH using custom-designed probes for SRSF3 and USP6 and RT-PCR were used to confi rm the rearrangement of these loci and presence of the novel fusion transcript, respectively. Results: Transcriptome sequencing analysis identifi ed the fusion of SRSF3 exon 1 to USP6 exon 2 in an ABC with t(6;17). RT-PCR confi rmed this fi ndings in both index ABC and NF, and also identifi ed a second splicing variant in which SRSF3 exon 1 was fused to the USP6 exon 1. Among 6 ABC and 7 NF with previously unknown USP6 partner genes, FISH and RT-PCR identifi ed 3 additional tumors (2 NF and 1 ABC) with the same SRSF3-USP6 fusion. One additional ABC was identifi ed with the typical NF fusion MYH9-USP6.
Conclusions:
We report the novel the fusion SRSF3-USP6 due to the translocation t(6;17) in both NF and ABC, and the typical NF fusion MYH9-USP6 in a skeletal ABC. These results support the impression that ABC and NF may belong to the same biologic spectrum of USP6-induced tumors with skeletal and soft tissue counterparts.
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Frozen Section Analysis and Its Relation to Multiple Factors in the Decision to Pursue Total Joint Arthroplasty DJ Fix, J Choi, AP Burke. University of Maryland Medical Center, Baltimore, MD. Background: The histologic evaluation has been considered to be the gold standard in diagnosis of periprosthetic joint infection. Numerous studies have examined the sensitivity and specifi city of frozen section (FS) histologic analysis, with end comparison to tissue and hardware culture results. Our study is an attempt to review the utilization of FS in the surgical decision to pursue revision arthroplasty with reimplantation of hardware versus antibiotic therapy and postponed reimplantation, and to examine it in regards to concordance with other modalities which aid in this decision. Design: A search (September, 2011 through July, 2013) for specimens from revision total joint arthroplasties was conducted. A total of 175 cases were identifi ed. Data was collected for the following parameters: decision to pursue revision arthroplasty vs postponement, gross visualization, FS result, permanent section (PS) result, and operative culture results. Results: Of 175 cases, 139 cases resulted in total joint athroplasty/revision (REV)and 36 with postponement of reimplantation (NOREV). In REV cases, 74% had a FS, with 92% being read as negative and 8% positive, as compared to FS performed in 42% of NOREV cases, of which 60% were positive and 40% negative, and a resultant positive predictive value (PPV) of 53% and a negative predictive value (NPV) of 94%. This is contrasted with gross visualization, which was positive for infection in 67% and negative in 33% of NOREV cases, and positive in 4% and negative in 96% of REV cases, with a PPV of 80% and a NPV of 92%. The NPV of FS compared to that for gross visualization indicates that it is a better test for "ruling out" infection. Average pair-wise Cohen's Kappa (CK) was 0.421 for all test categories, with notable CK values for operative decision versus gross visualization/FS/culture of 0.595/0.47/0.311, respectively. FS results showed a moderate correlation with reimplantation (CK=0.47), less correlation with culture results (CK=0.355), producing both PPV and NPV are similar to that of previous studies. There was a good correlation between FS and PS (CK=0.667), with PS showing a small increase in sensitivity. Conclusions: Gross visualization showed the highest correlation with decision regarding arthroplasty and culture results. FS is utilized more often in cases where the end decision is weighted towards REV rather than NOREV. The benefi t of FS over gross inspection is not clearly documented by this study.
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Primary Myxoma of Bone J Forcucci, K Lindsey, C Welsh, D Lucas, MT Smith. Medical University of South Carolina, Charleston, SC; The University of Michigan Health System, Ann Arbor, MI. Background: Myxoma of bone is a rare, benign, but locally destructive, recurrent neoplasm. Infrequently, these lesions present in the craniofacial bones and mimic other soft tissue tumors, radiologically, clinically, and histopathologically. We present three pediatric cases of primary myxoma of bone emphasizing the clinicopathologic presentation and diagnostic evaluation of this rare entity. Design: A retrospective search for cases of primary myxoma of bone within the surgical pathology fi les at two tertiary care centers was performed. Clinical, morphologic, and immunohistochemical data was analyzed. Results: Three cases of primary myxoma of bone were identifi ed. Each was located within the craniofacial bones of pediatric patients (age range 4-16). While the maxillary lesion was asymptomatic and discovered incidentally, the remaining cases found within the sphenoid were identifi ed secondary to mass effect and visual disturbances. All patients underwent successful subtotal resection and had no evidence of distant disease or recurrence at follow up (range 0-4 years). Grossly, the specimens were composed of heterogenous gelatinous and fi brous soft tissue ranging in size from 4.8 -5.3 cm. The histologic sections show a sparsely cellular gray-blue myxoid stroma with evenly spaced bland stellate cells replacing medullary spaces between normal appearing bony trabeculae. In two cases, the stellate cells divide the myxoid material into vaguely polygonal shapes, while in the third case a lightly streaming pattern is present. A delicate capillary network, reminiscent of loose chicken-wire, is apparent in each case. The myxoid material is variable ranging from stringy, eosinophilic, and mucinous to more gray, fi nely granular, and amorphous. Within the maxillary lesion, an Alcian Blue stain illustrates the differential staining between epithelioid (glandular cells) and stromal mucins (myxoid material) with loss of blue staining following hyaluronidase digestion. Immunohistochemical stains elaborated pertinent negative staining of the stromal cells with S100, and SMA. The cells were positive for vimentin, and showed a low proliferation index with ki-67 staining. Conclusions: Myxoma of bone is a rare lesion, particularly in the craniofacial bones, with a wide clinicopathologic differential diagnosis including metastatic atrial myxoma, chondroma, chordoma, and chondrosarcoma. Histologically, myxoma of bone recapitulates the features of other myxomas with bland stellate cells populating stromal material composed of mucins.
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Clinicopathological and Immunohistochemical (IHC) Analysis of 46 Cases of Myxoinflammatory Fibroblastic Sarcoma (MIFS) NM Harding-Jackson, JC Chang, E Zambrano, B Rubin, D Kazakov, C Bacchi, H Dominguez-Malagon, J Lamovec, G Falconnieri, S Suster. Background: MIFS is a rare low-grade tumor of modifi ed fi broblasts with a predilection for the distal extremities. Due to the diagnostic challenges posed by its varied morphology and nonspecifi c IHC features, further characterization may be helpful in distinguishing this entity from infl ammatory processes and malignant lesions of higher metastatic potential. Design: 46 cases of MIFS were retrieved. The clinical and histologic features were characterized, and immunophenotyping was performed using tissue microarray. Results: Patient ages ranged from 20 to 89 (median 47), with no gender predilection. The anatomic distribution was as follows: foot 26%, hand 24%, forearm 17%, calf/knee 15%, axial trunk 9%, proximal arm 5%, gluteus 2%, and proximal leg 2%. Histologic features showed varying amounts of myxoid and fi brotic stroma populated by a mixed infl ammatory cell infi ltrate. All 46 cases contained scattered large, bizarre-appearing tumor cells with vesicular chromatin, prominent inclusion-like nucleoli, and abundant eosinophilic and variably vacuolated cytoplasm. Seven of 46 cases (15%) contained focal areas with a solid, syncytial proliferation of neoplastic cells that outnumbered infl ammatory cells and spindle cells; however, areas of conventional MIFS were also present. By IHC, neoplastic cells exhibited strong nuclear positivity for cyclin D1 (86%), cytoplasmic positivity with distinct perinuclear dot-like accentuation for CD10 (79%), cytoplasmic positivity for PGP 9.5 (67%), and membranous positivity for D2-40 with occasional perinuclear dot-like expression (67%); tumor cells showed patchy positivity for CD63, CD34, and CD15 in 40%, 35%, and 29% of cases, respectively. Factor XIIIa and bcl-2 positivity were observed in 7% of cases. All cases were negative for AE1/AE3, S100, CD21, CD30, CD31, CD68, CD117, p63, ALK-1, FLI-1, GLUT-1, HBME-1, TLE-1, WT-1, MDM2, PAX-5, SOX-10, MITF, and beta-catenin.
Conclusions:
The presence of focal syncytial neoplastic cell growth is reported. We also propose novel markers, which may be of diagnostic utility, including frequent expression of cyclin D1, CD10, PGP 9.5 and D2-40. Due to its high sensitivity and striking perinuclear dot-like pattern, CD10 and D2-40 may be of particular interest. Background: Primary and secondary mutation status of gastrointestinal stromal tumors (GISTs) infl uence treatment response and disease progression. Our objective was to characterize primary and secondary mutations in a large cohort of GISTs including recently described KIT exon 8 deletions. Design: Primary site, size, and time from treatment start to sample acquisition of all GISTs that our lab performed mutation analysis on from 2009-2013 were reviewed. KIT exons 9 and 11 were screened for indels by a sizing assay. KIT exons 9, 11, 13, 14, 17; and PDGFRA exons 12 and 18 were sequenced. To screen for KIT exon 8 indels in cases lacking the above KIT/PDGFRA mutations ("wild type" cases), we performed a sizing assay of this exon. Results: Primary mutations were identifi ed in 226 out of 244 (92.6%) patients (table 1): 197 KIT mutations (exon 9: 1 colorectal, 21 small bowel; exon 11: 8 colorectal, 80 gastric; 75 small bowel, 2 omental, 2 esophageal; exon 13: 5 small bowel, 2 gastric, 1 multifocal familial), and 29 PDGFRA mutations (5 in exon 12: all gastric; and 24 in exon 18: 23 gastric, 1 omental). Primary mutation type was associated with site (p<0.001) but not size (p= 0.4). All available wild type cases were negative for KIT exon 8 mutations (0/13). Secondary mutations were identifi ed in 33/68 (48.5%) patients (table 1) . Four of 32 (12.5%) patients developed secondary mutations in KIT exons 13 and 17 between 12 and 15 months post imatinib. Secondary KIT mutations occurred mainly in the ATP binding pocket (exon 13: V643fs, Y646S, V654A, N655T; exon 14: T670I, N680K) and activation loop (exon 17: D820E/H/V, N822K/Y, Y823D). Five of 7 patients with primary KIT exon 9 mutations developed secondary KIT mutations: exon 11 (2), exon 13 (1) and exon 17 (2). Twenty-seven of 53 patients with KIT exon 11 mutations developed secondary mutations: exon 13 (11), exon 14 (1), exon 17 (14), and 1 KRAS exon 2 (G12V). One patient with a primary KIT exon 13 mutation (K642E) developed a second KIT exon 13 mutation (V654A). KIT primary mutation type correlated with secondary mutation (p=0.04).
Secondary KIT mutations are detectable between 12 and 15 months of imatinib initiation in 12.5% and in over 70% of patients after 33 months. KIT exon 8 indel mutations were not detected.
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Expression Immunohistochemistry for ROS1 has recently been shown to correlate with ROS1 rearrangement in pulmonary adenocarcinoma. The purpose of this study was to determine whether immunohistochemistry for ROS1 could predict ROS1 rearrangement in IMT. Design: In total, 30 IMTs were evaluated, including 21 ALK-positive tumors (10 confi rmed to harbor ALK rearrangements, with TPM3, CLTC, RANBP2, and FN1 fusion partners) and 9 ALK-negative tumors (including 2 known to harbor ROS1 rearrangements, with YWHAE and TFG fusion partners). Immunohistochemistry was performed on whole tissue sections following pressure cooker antigen retrieval using a rabbit anti-ROS1 monoclonal antibody (clone D4D6; Cell Signaling Technology; 1:100 dilution). The results were scored as "positive" or "negative", and the pattern of staining was recorded. Results: Three ALK-negative IMTs (including both tumors with known ROS1 rearrangements) showed immunoreactivity for ROS1, whereas all the ALK-positive IMTs were completely negative for ROS1. One ROS1-positive IMT (with ROS1-YWHAE fusion) showed strong, diffuse cytoplasmic and nuclear staining; one case (with ROS1-TFG fusion) showed weak, granular cytoplasmic staining; and one case (genotype unknown) showed strong, diffuse cytoplasmic and dot-like staining. Next-generation sequencing to determine the ROS1 fusion partner in the latter case is in progress. Conclusions: Expression of ROS1 correlates with ROS1 rearrangement in IMT. These fi ndings suggest that immunohistochemistry for ROS1 may be useful to confi rm the diagnosis of a subset of IMTs, and also raise the possibility that some patients with clinically aggressive ALK-negative IMTs may be candidates for targeted therapy directed against ROS1. Whether the pattern of ROS1 staining correlates with the gene fusion partner remains to be determined.
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Delta-Like 1 Homolog (Dlk1) Is a Useful Marker for Diagnosis of Rhabdomyosarcoma H Ikeda, H Kimura, S Kitamura, A Ooi. Kanazawa University Hospital, Kanazawa, Ishikawa, Japan. Background: Delta-like homolog (Dlk1), a member of the epidermal growth factor family, is expressed in several organs during development, and has been detected in various carcinomas. Recently, the relationship between Dlk1 and skeletal muscle regeneration has been reported in rodent experiments and implicated to associate with myogenic tumor. Occasionally, it is diffi cult to discriminate between alveolar rhabdomyosarcoma and other small round cell tumor, also spindle or pleomorphic rhabdomyosarcoma and high grade sarcomas. We examined the expression of Dlk1 in rhabdomyosarcoma and various sarcomas, similar in morphology. Design: We collected 40 cases of rhabdomyosarcoma (7 cases were embryonal type, 10 cases were alveolar type, 6 cases were spindle type, 17 cases were pleomorphic type). The cases of Ewing sarcoma, desmoplastic small round cell sarcoma were used for control disease of alveolar rhabdomyosarcoma, and the cases of leiomyosarcoma, liposarcoma, undifferentiated sarcoma were used for control disease of spindle/pleomorphic rhabdomyosarcoma. We examined Dlk1 expression using immunohistochemistry.
Results: The expression of Dlk1 was not seen in non-neoplastic skeletal muscle in human. The cytoplasmic staining of Dlk1 was found in rhabdomyosarcoma cells in various degree. The percentage of Dlk-1-positive rhabdomyosarcoma was 100% in embryonal type, 100% in alveolar type, 83% in spindle type, and 88% in pleomorphic type. Dlk-1 was almost negative in control diseases except 1 case of Ewing sarcoma and undifferentiated sarcoma. The distribution of DLK-1-positive cells were not similar to myogenin or desmin.
Conclusions:
The expression of Dlk-1 was frequently seen in all subtype of rhabdomyosarcoma and Dlk-1 was almost negative in sarcomas similar in morphology. Dlk-1 seems to be useful marker for the histological diagnosis of rhabdomyosarcoma and also decision of tumor area.
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Lentiviral Delivered PPARg ShRNA Improves Bone Microarchitecture by Altering the Balance of Osteogenesis and Adipogenesis AW James, J Shen, K Khadarian, S Pang, C Chung, R Goyal, G Asatrian, X Zhang, K Ting, C Soo. UCLA, Los Angeles, CA. Background: Skeletal aging is associated with an increase in bone marrow adiposity. Recent study has focused on the role of adipokines and their negative impact on bone maintenance. A novel therapy for osteoporotic bone loss may be to target intramedullary adipogenesis. PPARgamma (PPARg) is considered the master regulator of adipogenesis. Here, we designed a lentiviral delivery system for PPARg shRNA, and examined its effects in an intramedullary injection model. Design: PPARg shRNA was delivered by a lentiviral vector. In vitro testing confi rmed purity, concentration, and effi cacy. Next, control (GFP) lentivirus or PPARg shRNA expressing lentivirus were delivered by injection into the femoral intramedullary space of SCID mice. At four weeks post injection, analysis was performed, including high resolution micro CT, histology and histomorphometry, and immunohistochemistry for markers of adipocytes, OBs, and OCs. Results: PPARg shRNA delivery reduced Pparg expression in BMSC, accompanied by a reduction in adipogenic differentiation.
In vivo, a near total reduction in mature marrow adipocytes was observed. This was accompanied by reductions in adipocyte markers PPARg and FABP4.
Unexpectedly, trabecular bone was increased by microCT and histomorphometric analyses. Immunohistochemistry demonstrated an increase in the number of bone-lining OBs and a decrease in multinucleated OCs. Conclusions: These findings suggest that loss of PPARg in the bone marrow compartment has a signifi cant role beyond anti-adipogenic effects. Specifi cally, we found improved trabecular bone microarchitecture, increased osteoblastic and decreased osteoclastic effects. PPARg silencing may either have had a direct effect on OB and OC cell types, or altered the adipokine milieu to favor intramedullary bone formation.
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Epithelioid Malignant Peripheral Nerve Sheath Tumor: Clinicopathologic Features of 48 Cases VY Jo, CDM Fletcher. Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Background: Epithelioid malignant peripheral nerve sheath tumor (EMPNST) is rare and may be confused with melanoma. It differs from conventional MPNST by showing diffuse S-100 staining, infrequent association with NF1, and occasional origin in a schwannoma. Loss of INI1 expression is seen in a subset of tumors. We describe the clinicopathologic features of this distinct variant in a large series. Design: 48 cases were identified in consult files (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . HE and immunohistochemical stains were examined. Follow-up data was obtained from referring pathologists. Results: Patients were 23 men and 25 women, median age 42.5 years (range 6-80). Anatomic sites were: lower extremity (20), upper extremity (3), neck (2), trunk (16), lip (2), visceral (5). In somatic sites, 4 were dermal, 24 subcutaneous, and 7 subfascial. Grossly tumors were well-circumscribed and cystic, fi rm, or lobular; 4 were associated with a nerve. Size range was 0.4-16 cm (median 2.95). Most tumors showed characteristically multilobulated growth of relatively uniform but atypical epithelioid cells; 4 were circumscribed nodules and 2 had solid sheetlike growth. Tumor cells had round nuclei and abundant amphophilic cytoplasm; some had spindled or myxoid foci. 7 tumors showed mild atypia with vesicular round nuclei and small nucleoli. The remainder showed moderate-to-severe atypia with irregular vesicular nuclei and prominent nucleoli. Mitoses ranged from 0-46/10 HPF; atypical forms were seen in 7 cases. 6 tumors had necrosis, all with at least moderate atypia and frequent mitoses. 3 tumors arose in a schwannoma and 1 in a neurofi broma (in an NF1-patient). All tumors expressed S-100: 46 strong and diffuse, 2 multifocal. Mart-1/Melan A (0/45) and HMB-45 (0/47) were negative. GFAP was often positive (23/38); keratin was negative (0/23). For EMA, 4/25 showed rare positive cells and a capsule was highlighted in 6 cases. INI1 expression was lost in 28/42 tumors (67%). Most patients were treated by resection (5 marginal, 15 with wide margins). Follow-up data is available for 14 patients so far (range 3-144 months): 3 developed local recurrence, 3 had metastases, 6 are alive with no evidence of disease; 2 died of disease. Conclusions: EMPNST is a distinct variant that affects adults most frequently on the lower extremity, though a wide age range and site distribution are seen. Most are diffusely S-100 positive and two thirds of tumors show INI1 loss. Based on preliminary data, there is a risk of recurrence and metastases; better prognosis may be associated with completely excised small superfi cial tumors.
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Relevance of FNCLCC Grade and MDM2 Amplification Levels in Dedifferentiated Liposarcoma G Jour, A Gullett, M Liu, BL Hoch. University of Washington Medical Center, Seattle, WA; University of Washington, Seattle, WA. Background: Dedifferentiated Liposarcoma (DDLS) is a form of liposarcoma occurring mostly in the retroperitoneum. A limited number of studies have shown no reliable prognostic factors other than anatomical site. Molecular markers of tumor behavior, including amplifi cation levels of MDM2 and CDK4 genes, have been explored in only a very small number of cases. Furthermore, the prognostic value of grading is uncertain in DDLS. Herein, we investigate whether FNCLCC grade and MDM2 gene amplifi cation levels have prognostic value in DDLS in terms of local recurrence (LR) and disease free survival (DFS). Design: 50 cases were retrieved. Cases were reviewed and FNCLCC grade was scored for the dedifferentiated component. Testing for MDM2 gene amplifi cation was performed by fl uorescence in situ hybridization (FISH). 40 nuclei were counted for each case. Amplifi cation was categorized as high-level when one nucleus had 20 or more MDM2 copies, and as low-level when it had less than <20 copies. Follow up data was obtained through chart review and phone calls to clinicians. Log rank test and Cox proportional hazards models were used to determine the effect of grade and level of amplifi cation on LR and DFS outcomes. Results: Our series includes 50 patients [male n=28, female n=22] with an average age of 63 years old (range 28-88) and a median follow up of 28 months (range 2-120). Tumors were graded as grade 1 (6%), grade 2 (58%), and grade 3 (36%). Tumor sites included retroperitneum (68%) and other sites (32%). When adjusted for age, sex, site, tumor size, and margin status, grade 3 patients had a higher recurrence rate than grade 1 and 2 (HR=2.07, 95% CI: 1.24, 7.62; p=0.015). Patients with high level of MDM2 amplifi cation (>20) had higher recurrence rate on univariate (p=0.028) but not on multivariate analysis (HR = 1.69, 95% CI: 0.73, 3.94; p=0.221). No signifi cant association was seen between FNCLCC grade or level of amplifi cation and DFS. Furthermore, no signifi cant association was noted between amplifi cation and grade (2 = 1.48, p = 0.221). Conclusions: FNCLCC grade 3 dedifferentiation confers a worse prognosis in DDLS in terms of local recurrence. MDM2 amplifi cation level remains a useful diagnostic tool in DDLS, but has no prognostic value in terms of local recurrence. Additional studies investigating potential biomarkers such as CDK4 gene are warranted. This may yield an integrative grading system for DDLS combining both molecular and morphological parameters.
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Loss of p16 (CDKN2A) Expression Is Rare in Dedifferentiated Liposarcoma and Does Not Promote Tumor Progression Y Kang, AE Horvai. UCSF, San Francisco, CA. Background: Well-differentiated liposarcoma (WDL) and dedifferentiated liposarcoma (DDL) constitute the most common subgroup of liposarcomas and may represent a time-dependent form of tumor progression from lipogenic to non-lipogenic phenotype. WDL and DDL share amplifi cation of chromosome subregion 12q13-15 resulting in amplifi cation of the MDM2 and CDK4 genes. Overexpression of the MDM2 and CDK4 proteins likely leads to loss of cell cycle G1control and initiation of tumorigenesis but the mechanisms of progression from WDL to DDL are poorly understood. Recent studies indicate that the p16 protein (a product of the CDKN2A gene) is commonly expressed in WDL. The p16 tumor suppressor plays an antagonistic role to CDK4 by preventing CDK4-mediated inactivation of Rb and loss of p16 occurs during neoplastic progression in some malignancies. In a subset of liposarcomas, loss of p16 may compensate for absence of CDK4 amplifi cation, but the role of p16 in progression is unknown. In this study, we investigate the correlation between p16 expression and progression to a nonlipogenic phenotype, and the relationships between p16 expression and copy number changes of CDKN2A and CDK4. Design: Twenty-one cases of DDL with chromosome 12q13-15 amplifi cation previously confi rmed by array comparative genomic hybridization (aCGH) and known MDM2 and CDK4 expression status were identifi ed from the departmental archives. Matched lipogenic and non-lipogenic components of the DDL were immunostained for p16 using standard methods. Staining was scored on a scale of 0-3+, based on the fraction of cells and intensity of staining. The p16 results were compared to aCGH and IHC data for copy number changes and CDK4 expression, respectively. Results: All DDL were positive for p16 with complete concordance between staining scores for matched lipogenic and non-lipogenic components. Specifi cally, 20 tumors (95%) demonstrated strong, diffuse (3+) p16 staining in both components. One tumor (5%) showed weak, focal (1+) p16 staining in both components and a corresponding decreased copy number of 9p21.3, in the region of CDKN2A. This tumor also lacked CDK4 gene amplifi cation and CDK4 protein expression in both components.
Conclusions:
The concordance between p16 staining in matched components of DDL suggests that p16 loss likely does not mediate progression to a non-lipogenic phenotype. In a small subset of DDL, allelic deletion of CDKN2A results in decreased p16 expression, and may compensate for absent CDK4 amplifi cation, but this is likely an early event in tumorigenesis.
64
Diagnostic Utility of p16 Immunohistochemistry in Distinguishing Dedifferentiated Liposarcomas from Other Retroperitoneal Sarcomas Y Kang, AE Horvai. UCSF, San Francisco, CA. Background: The family of well-differentiated and dedifferentiated liposarcomas (WDL and DDL, respectively) are among to most common soft tissue sarcomas in adults. Both WDL and DDL demonstrate amplifi cation of chromosome subregion 12q13-q15 with resultant overexpression of the MDM2 and CDK4 genes. Consequently, immunohistochemistry (IHC) for the MDM2 and CDK4 proteins is often used to confi rm the diagnosis of WDL and DDL. Recent studies have suggested that IHC for p16 (the product of the CDKN2A gene) may be a useful adjunct to MDM2 and CDK4 to differentiate WDL from benign adipocytic tumors. However, the utility of p16 IHC to distinguish DDL from morphologic mimics is unknown. In this study, we examine the utility of p16 IHC in differentiating DDL from other retroperitoneal spindle cell malignancies. Design: This study compared 44 high-grade DDL to 32 other high-grade retroperitoneal sarcomas for the presence of p16 immunohistochemistry. All DDL showed 12q13-15 amplifi cation and/or positive IHC for MDM2 and CDK4, whereas the control sarcomas lacked MDM2, CDK4 and a WDL component. Based on clinicopathologic features, the control sarcomas consisted of leiomyosarcoma (LMS, n=10), undifferentiated pleomorphic sarcoma (UPS, n=13), sarcomatoid carcinoma (SCA, n=7), endometrial stromal sarcoma (ESS, n=1) and malignant gastrointestinal stromal tumor (GIST, n=1). IHC for p16 was performed on paraffi n-embedded whole tissue sections using standard methods and the slides were scored 0 to 3+ based on intensity and fraction of cells staining. Results: IHC stain results for p16 are summarized in Table 1 . Although p16 staining was more common in DDL than the control sarcomas as a group, the difference was greatest when compared to SCA. By contrast, retroperitoneal LMS could not be distinguished from DDL by p16 status. The sensitivity of p16 for DDL was 98% with negative predictive value of 91%, but specifi city (31%) and positive predictive value (67%) were low when comparing to other retroperitoneal sarcomas. Conclusions: These results demonstrate the utility of p16 in the diagnosis of retroperitoneal sarcomas insofar as a negative p16 result largely excludes the diagnosis of DDL. However, a positive result lacks suffi cient specifi city to exclude other sarcomas, especially LMS.
Impact of Fluorescence In Situ Hybridization Analysis on the Final Diagnosis of Dermatofibrosarcoma Protuberans: About 448 Cases
Background: Dermatofibrosarcoma protuberans (DFSP) is a rare superficial mesenchymal tumor of intermediate malignancy, locally aggressive but rarely metastasizing. Cytogenetically, most DFSP is characterized by chromosomal rearrangements resulting to the COL1A1-PDGFB fusion gene. This abnormality can be detected by fl uorescence in situ hybridization (FISH) analysis in routine practice. The aim of this study was to evaluate the role of the molecular analysis in the diagnosis of DFSP. Design: 448 cases referred for second opinion or for confi rmation of a diagnosis of DFSP since 2007 to 2013 were studied. For these cases a FISH had been performed to detect the COL1A1-PDGFB fusion gene. All cases were reviewed by two pathologists and classifi ed in three categories according to the probability of the DFSP diagnosis before molecular analyses. The case was "certain" when DFSP was the only possible diagnosis; "probable" when DFSP remained the fi rst diagnosis, but other differential diagnosis existed; "possible" when DFSP was considered as a differential diagnosis. Final diagnosis was supported by clinico-pathological fi ndings and results of FISH analyses. Immunohistochemical analysis of CD34 was systematically performed and other markers when necessary. FISH assay was performed using the Histology FISH accessory kit (Dako R ) and home-made probes. Results: For the 200 "certain" cases, 178 (89%) FISH analyses were positive, 7 (3.5%) negative and 15 (7.5%) non interpretable (NI). For the 121 "probable" cases: 103 (85%) FISH analyses were positive, 8 (6%) were NI and 10 (9%) were negative. For these 10 cases, fi nal diagnoses were: 1 low-grade myofi broblastic sarcoma, 3 undifferentiated sarcomas, 2 solitary fibrous tumors, 1 spindle cell lipoma, 1 perineurioma, 2 undifferentiated spindle cell tumors without malignant evidence. For the 127 "possible" cases: 91 (71%) FISH analyses were negative, 14 (12%) were NI and 22 (17%) were positive. In these 22 cases, 7 undifferentiated sarcomas were fi nally considered as fi brosarcomatous DFSP, 4 myxofi brosarcomas as myxoid DFSP, 2 dermatofi bromas, 2 reactive lesions, 1 solitary fi brous tumor, 1 perineurioma, 1 myoepithelioma, 1 benign nerve sheath tumor, and 3 undifferentiated spindle cell tumor without malignant evidence as DFSP. FISH analysis has been helpful for confi rming the diagnosis of DFSP in 23% of cases (103 / 448) and necessary for the diagnosis of DFSP in 5% of cases (22 / 448). Conclusions: This study highlights the important role of the FISH analysis in the diagnosis of DFSP.
FOSL1 Protein Is Differentially Overexpressed in Desmoplastic Fibroblastoma and a Subset of Fibroma of Tendon Sheath I Kato, T Motoi, Y Fukuda, A Yoshida, M Ogawa, H Koiwai, S Horiguchi, T Goto, T Hishima. Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome
Hospital, Tokyo, Japan; National Cancer Center Hospital, Tokyo, Japan. Background: Desmoplastic fi broblastomas (DFBs) and fi bromas of tendon sheath (FTSs) are benign fi broblastic tumors that comprise bland spindle cells. A recurrent chromosomal rearrangement involving 11q12 locus has been reported in DFBs and FTSs, suggesting a genetic link between the 2 entities. Recently, a microarray analysis of DFBs revealed mRNA elevation of FOSL1, which encodes a nuclear leucine zipper protein. As the FOSL1 gene is located close to 11q12, it has been proposed as a candidate involving the 11q12 rearrangement. We here explored the diagnostic potential of FOSL1 immunohistochemistry by studying DFBs, FTSs and their histological mimics. In addition, we investigated FOSL1 rearrangement status in selected cases. Design: FFPE samples of 9DFBs and 10FTSs were immunostained by using anti-FOSL1 monoclonal antibody. Ten desmoid-type fi bromatoses (DMFs), 10 nodular fasciitis (NDs), 10 superfi cial fi bromatoses (SFs), 6 spindle cell lipomas (SLs), and 3 neurofi bromas (NFs) were also stained as histological mimics. Only nuclear reactivity was considered signifi cant. The results were graded as 2+ (>50% of tumor cells stained with strong intensity), 1+ (10-50% of cells stained with strong intensity or≥10% of cells stained with weak intensity), or 0 (<10% of cells stained with weak intensity). FOSL1 gene status was examined on FFPE samples of 6DFBs, 2FTSs, 1ND, and 1DMF, by using dual-color chromogenic in situ hybridization (CISH) with custom-made breakapart probes spanning FOSL1. Results: All DFBs (9/9) showed 2+ FOSL1 immunopositivity, whereas 50% (5/10) of FTSs showed 2+ reactivity. The remaining FTSs showed 1+ (30%, 3/10) or 0 (20%, 2/10) staining. Histological appearance of FTSs did not predict FOSL1 expression status. Other spindle cell tumors showed 1+ (25%, 10/40) or 0 (75%, 30/40) reactivity. None of the cases examined by CISH showed FOSL1 break-apart signals. Conclusions: Strong diffuse immunoreactivity of FOSL1 distinguishes DFBs from histological mimics such as DMFs. In contrast, similar overexpression was seen only in a subset of FTSs, suggesting that FTSs may not be a uniform tumor entity; FOSL1-overexpressing subset may be related to DFBs and might harbor 11q12 rearrangement. Our CISH analysis indicated that the FOSL1 is not rearranged in DFBs or FTSs, and suggested that FOSL1 expression may be induced by other mechanisms.
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MYC Immunohistochemistry and FISH Are Useful in the Diagnosis of Postradiation Angiosarcoma V Khachaturov, R Kwan, J Tripodi, RA Garcia, V Najfeld, EG Demicco. Mount Sinai Medical Center, New York, NY. Background: Postradiation vascular neoplasia in the breast includes benign atypical vascular lesions (AVL) and malignant angiosarcomas (AS). Accurate differentiation between the two lesions is essential for appropriate clinical management and prognosis. Recently, recurrent genetic abnormalities, including high level amplifi cation of MYC, FLT4 and 10p12.33, were reported in postradiation AS and not AVL or primary AS. In order to determine the diagnostic value of these molecular alterations and assess immunohistochemical correlates, we evaluated a series of postradiation vascular proliferations of the breast for amplifi cation of MYC, FLT4, 10p12.33 and Prox1 and for MYC expression by immunohistochemisty (IHC). Design: Postradiation vascular lesions of the breast were retrieved from institutional pathology archives. HE slides were reevaluated by 2 soft tissue pathologists and classifi ed as AVL or AS. Formalin-fi xed paraffi n-embedded (FFPE) tissue was stained for MYC (Y69, Ventana). Nuclear stain was scored from 1+ (weak) to 3+ (strong), with only 2-3+ staining considered positive. Fluorescence in situ hybridization (FISH) was performed on 4-mm FFPE sections using locus specifi c custom probes for MYC (8q24.21), FLT4 (5q35.3), 10p12.33 and Prox1 (1q41) (Empire Genomics). Amplifi cation was defi ned as >9 signals in >25% of counted nuclei. Results: Patients included 18 females with 22 AS and 8 with AVL. MYC and FLT4 amplifi cation were detected in 86% and 9% of AS, respectively. No amplifi cation of Prox 1 or 10p12.33 was detected in any AS. All AVLs tested showed no amplifi cation for MYC, FLT4, 10p12.33 and Prox1 (Table 1 ). All MYC IHC positive cases demonstrated MYC amplifi cation, while 5 cases with MYC amplifi cation gave false negative IHC results. All cases of AVL were negative for MYC (Table 2) . Design: We performed WES on 20 RMS (9 ARMS, 11 ERMS). We also genotyped additional ERMS samples using mass spectrometry-based genotyping (Sequenom). We collected clinicopathologic data and performed survival analyses and functional studies. Results: By WES, 2 ERMS showed the same c.365T>G somatic point mutation in MYOD1, leading to an L122R substitution. The L122R mutation occurs in the conserved basic region of the DNA-binding domain of MYOD1, at a highly specifi c residue that is a leucine (L) in all myogenic bHLH TFs (MYOD1, MYF5, myogenin, MRF4) but is an arginine (R) in MYC. We genotyped an additional 93 ERMS for the L122R mutation using Sequenom genotyping. The mutation was found in 8 additional cases, resulting in an overall prevalence of 10% (10/104). The 10 ERMS with the MYOD1 L122R mutation were highly cellular with frequent spindle cell morphology and uniform strong immunopositivity for MYOD1, suggesting, in some cases, an overlap with the recently described adult spindle cell variant of ERMS. Notably, 9 of the 10 ERMS with MYOD1 mutations were diagnosed in adolescence or adulthood (mean age = 25; median age = 28), and they were more likely to arise in the head/neck (8/10 vs 16/80; p=0.0003). Furthermore, the overall survival with MYOD1-mutant ERMS was signifi cantly poorer than for ERMS lacking MYOD1 mutation (0% vs 48% at 10 yrs; p=0.02). We also observed a relationship between MYOD1 L122R and PIK3CA mutations in 66 cases with genotyping data for both: PIK3CA mutations were seen in 3/10 MYOD1 L122R cases vs 0/56 MYOD1 wild type cases (p=0.003), suggesting possible cooperation between these mutations. Functional studies in C2C12 cells confi rmed that MYOD1 L122R blocks myogenic differentiation and enhances proliferation. Conclusions: ERMS with MYOD1 L122R represents a novel molecular subset of RMS with distinctive clinicopathologic features that should be considered for high risk protocols and targeted therapeutic development. Background: The sinonasal cavities give rise to a heterogeneous group of neoplasms of mesenchymal, neural, epithelial, melanocytic and hematopoietic origin. These account for less than 1% of all cancers, but their overall frequency is unclear . Recurrence and treatment options are variable depending of the hisopathological profi le of the cancer. Design: We retrospectively reviewed all non-epithelial malignancies of the sinonasal cavities at a tertiary care center. Results: Of 720 sinonasal neoplasms from 2003-2013, 37 cases (5%) were non-epithelial neoplasms. These were comprised of sarcomas (n=11), mucosal melanomas (n=8), benign neoplasms (n=7), lymphomas (n=2), and germ cell tumors (n=1). Of the 37 study cases, 9 arose from bone. Of the sarcomas, four were chondroblastic osteosarcomas of the maxillary bone and the nasal cavity, exclusively in males 33-62 years old, with two tumors being recurrent. Alveolar type rhabdosarcoma for the ethmoid and maxillary sinuses was seen in one male and one female 52 and 57 years of age respectively; recurrence was seen in one patient. One of each of the following malignant soft tissue tumors were seen: a low grade fi bromyxoid sarcoma of the nasal cavity in a 23 year old male with no known recurrences, a spindle cell sarcoma of the frontal, maxillary and sphenoid sinuses in a 58 year old male, a myxoid liposarcoma of the maxillary tuberosity in a 13 year old male with known multiple recurrences, and a angiosarcoma of the nasal septum in a 78 year old male. Of the borderline malignancies, the following tumors were observed: a hemangiopericytoma of the nasal cavity in a 49 year old male with no recurrences, a desmoplastic fi broma of the maxilla in a 50 year old male, and fi ve cases of fi brous dysplasia occurring mostly in the maxillary and ethmoid sinus in two females and three males 15-56 years old, with most patients experiencing multiple recurrences. Mucosal malignant melanomas of the nasal cavity, maxillary and ethmoid sinuses were seen in eight patients fi ve of which were females and three were males 51-97 years old with multiple recurrences in 6 cases. Two large B-cell lymphomas were observed in a male and a female patient 52-57 year of age. There was a case of a nasal cavity teratoma in a 10 year old boy with numerous recurrences and eventual death. Conclusions: In our study non-epithelial neoplasms constituted 5% of primary sinonasal tumors, malignant in their majority, often aggressive with multiple recurrences, heterogeneous, with soft tissue sarcomas most frequent. 
Conclusions: CD24 expression was robust in
LGFMS but undetected in other lesions in the differential, with scattered expression in high grade sarcomas and other lesions studied. These fi ndings suggest that CD24 induction is a specifi c feature of the molecular alterations pathognomonic for LGFMS and may by useful as a diagnostic surrogate. Background: Myxofi brosarcoma (MFS), an infi ltrative sarcoma, typically occurs in superfi cial tissues of elderly patients' extremities. Historically, up to 50% have local recurrence (LR) and up to 35% develop distant metastases (DM). Prior grading schemes have not predicted clinically aggressive behavior. We studied a series of MFS, all resected in an oncologic fashion at a single institution, to determine if historic LR/DM rates persist and to identify histologic predictors of clinical outcome. Design: Review of our Pathology database identifi ed 46 MFS cases resected between 2003 and 2013 which underwent defi nitive excision at our institution. Some cases had prior outside diagnostic biopsy, all reviewed at our institution. Only cases with slides of the original tumor available for review were included. Histologic (ie, margin status, percent non-myxoid stroma, grade by the French system) and clinical (ie, treatment received, LR, DM, status) parameters were assessed. Results: Our 46 cases (22 male, 24 female) mainly arose in the elderly (mean 66 years, range 42-89) with one tumor in a 29 year old female. Tumors ranged from 2-22 cm. Initial resection margins were positive in 23 (53%). 5 patients required 2 re-excisions to achieve negative margins on the initial tumor, including one that required amputation. 12/46 initial tumors (26%) had less than 25% non-myxoid stroma. Clinical follow up (mean 48 months) was available for 35/46 (76%). 1/35 (3%) died of disease at 24 months. 8/35 (23%) had LR (mean 18 months, range 6-47 months); 6/8 with LR had negative margins on initial excision, including 4 patients with > 0.5 cm margins, 2 < 0.5 cm and 2 < 0.1 cm. 12/35 (34%) had more than one LR. 2 patients with LR required amputation for local control. 7/35 (20%) developed DM (mean 20 months, range 4 -77) to the lung (4), lymph nodes (2), axilla (1), thigh (1); 1 patient had 2 DM. By the French system 6/7 (86%) patients with DM had high grade and 1/7 (14%) intermediate grade tumors; all (7/7 (100%)) patients with DM had > 25% non-myxoid stroma. Conclusions: Our series of MFS indicates that historic rates of LR persist, although rates of DM are lower. MFS is a clinically aggressive tumor with LR in 8 (23%) patients and DM in 7 (20%) in our series. All patients with DM had > 25% non-myxoid stroma in the initial tumor; the initial tumor was also high grade by the French system in 6/7. We are expanding our series through identifi cation of additional cases with longer follow up to further investigate the effect of non-myxoid stroma and French grade on clinical prognosis. 
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MYC Expression in Sporadic and
Background:
The MYC proto-oncogene(8q21) regulates genes involved in cell division, cell growth, and apoptosis. Amplifi cation of MYC resulting in its overexpression has been described in radiation associated mammary angiosarcoma. However, the role and prevalence of Myc expression in sporadic and other radiation-associated sarcomas has not been extensively investigated. Design: 53 radiation-associated sarcomas(49 undifferentiated pleomorphic sarcomas (UPS), 2 liposarcomas, and 2 osteosarcomas),119 sporadic sarcomas(12 liposarcomas, 18 synovial sarcomas, 4 leiomyosarcomas, 71 UPSs, 14 unclassifi ed sarcomas), and 27 radiation associated angiosarcomas(for comparison) were analyzed using formalin-fi xed paraffi n-embedded tissue microarrays. Immunohistochemical studies were performed using the rabbit monoclonal anti-Myc antibody to the N terminus of human Myc (Y69; Ventana Medical Systems, Tucson, AZ, USA). Immunoreactivity was graded for intensity(weak, moderate, and strong). Any labeling was considered positive. Results: In sporadic sarcomas, MYC reactivity was observed in 87 of 119 cases (73%); 17 of which had moderate to strong labeling. These were seen in UPS(12), synovial sarcoma(2), unclassifi ed sarcoma(2), and leiomyosarcoma(1). In radiation-associated sarcomas(non-angiosarcoma), 22 of 53 cases(47%) had MYC expression, 17 cases with weak and 7 cases, all UPS, with moderate to strong labeling. In contrast, MYC was expressed in 26 of 27(96%) radiation-associated angiosarcoma, with predominantly diffuse and strong labeling(20/26). Conclusions: Variable MYC expression, including occasionally moderate to strong labeling, can be seen in sarcomas other than angiosarcomas including other radiationassociated sarcomas though less than radiation associated angiosarcomas. These fi ndings suggest that MYC may play a role in tumoriogenesis in sarcomas and may serve as a potential therapeutic target. The mechanism of overexpression in these tumors has yet to be elucidated. Background: Myxofi brosarcoma is genetically complex and insuffi ciently characterized in molecular determinants of clinical aggressiveness. By reappraising the public transcriptome (GSE21122), EZH2 was identifi ed as a top-ranking differentially upregulated gene among those regulating chromatin organization (GO:0006325) in myxofi brosarcoma tissues. Design: To validate the pathogenetic role of EZH2 in myxofi brosarcoma, mRNA abundance and protein expression of EZH2 were determined in independent samples by branched-chain DNA (bDNA) and immunohistochemical assays, yielding 40 and 87 informative cases, respectively. In vitro, RNA interference and DZNep treatment (targeting EZH2 associated PRC2 complex) were applied in EZH2-expressing myxofi brosarcoma cell lines to evaluate for the biological functions and therapeutic relevance of EZH2. The in vivo effect of DZNep treatment was examined in xenograft models established from two myxofi brosarcoma cell lines. Results: EZH2 protein overexpression was associated with higher histological grade (p=0.002), worse disease-specifi c and metastasis-free survival (both p0.0001), and mRNA upregulation (p=0.010). In all myxofi brosarcoma cell lines, stable EZH2 knockdown resulted in impaired cell proliferative, migratory, and invasive capabilities with concomitant reductions in anchorage-independent colony formation and wellformed endothelial tubes. In vitro, DZNep caused dose-and time-dependent cytotoxicity and downregulated PRC2-associated proteins with induction of cellular apoptosis and attenuation of EZH2 promoter transactivity. The dose-dependent therapeutic effi cacy of DZNep was further corroborated in vivo in both xenograft myxofi brosarcoma models. Conclusions: EZH2 overexpression plays an oncogenic role in myxofi brosarcoma pathogenesis and promotes tumor growth, migration/invasion, and angiogenesis, hence conferring clinical aggressiveness and representing a novel therapeutic target of DZNep therapy.
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MYC Expression in Mammary Vascular Tumors
atypical vascular proliferation. However, the prevalence of MYC expression and its diagnostic utility in evaluating primary mammary vascular tumors have not been extensively studied. Design: Formalin-fi xed paraffi n-embedded tissue microarrays and whole tissue sections of 20
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MicroRNA Expression Profiling Identifies Potential Prognostic Biomarkers in Osteosarcoma
The most important post-adjuvant prognostic factor of osteosarcoma (OSA) is pathologic response to chemotherapy, evaluated only by a crude assessment of post-treatment necrosis (>90% necrosis predicting a better outcome). Improved prognostic markers are needed to predict recurrences, metastases, and therapeutic responses, ideally prior to adjuvant therapy. MicroRNAs (miRNA) are non-coding RNAs with regulatory functions and their differential expressions have been described in OSA. We compared the miRNA expression profi les in osteosarcomas from patients with good and poor outcomes to identify specifi c miRNAs with useful prognostic associations on formalin-fi xed paraffi n embedded (FFPE) tissue. Design: RNA was extracted from 20 decalcifi ed FFPE pretreatment high-grade OSA biopsy specimens: 10 tumors from patients with disease-free survival in follow-up (good outcome), and 10 tumors from patients with recurrences and metastases (poor outcome). MiRNA expression profi ling was performed using a real-time PCR based platform on a Taqman Human miRNA array card containing 378 annotated miRNAs. Expression was normalized to housekeeping miRNAs. Expression level changes of 2.3 folds were considered signifi cant. Two sample t-tests were used on a probe-by-probe basis to compare the two groups with p-value <0.05 being considered statistically signifi cant. Results: The patients in good outcome group had a median clinical follow-up of 90.5 (range 51.8-113) months without metastases. Within the poor outcome group, all patients had distant metastasis with nine expired at a median survival of 29 (range 13.7-84.9) months and one under palliative care at 28 month follow-up. Two sample 2 fold) , miR-10b(9.8 fold), miR-22(8.4 fold), miR-18a(8.1 fold), let-7a(7.8 fold), miR-140(6.2 fold), miR-186(4.9 fold), miR-361(3.1 fold), and miR-148a(2.6 fold) expressions were signifi cantly higher in the good outcome group. Conclusions: We identifi ed a subset of miRNAs that differentiated between OSAs with good and poor outcomes by using formalin fi xed paraffi n-embedded tissue, irrespective of tumor necrosis. Many of these miRNAs are known to regulate genes associated with apoptosis, metastasis, and cell growth including the PI3kinase pathway. miRNA show promise as useful clinical prognostic biomarkers.
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Desmoid-Type Fibromatosis: Radiologic-Pathologic Correlation and Clinical Predictors of Recurrence in an 18-Year Retrospective Cohort JG Mantilla Arango, EM Shustef, E Villanueva-Siles. AECOM/Montefi ore Medical Center, Bronx, NY. Background: Desmoid-type fi bromatosis is a relatively rare, locally aggressive, fi brous neoplasm with an extensive differential diagnosis. These tumors are estimated to have a 20-45% risk of recurrence. Higher risk of recurrence has been associated with age, tumor size, and mutation of the CTNNB1 gene. We aimed to establish specifi c criteria to predict the risk of recurrence and help guide individualized surveillance and treatment. Design: We conducted a retrospective cohort study of 51 patients diagnosed with desmoid-type fi bromatosis between 1995 and 2008. The subset of patients and clinical information was extracted from our clinical information system using Clinical Looking Glass; Emerging Health Information Technology, Yonkers, NY. We reviewed initial imaging modalities, diagnoses, and recurrence rates 5-13 years post-diagnosis. Risk of recurrence was determined based on age, sex, race, anatomic site, and surgical margin status. Results: Of 51 patients, 18 developed post-operative recurrences during follow-up (34.6%). Mean time to recurrence was 18.3 months. Females were more frequently affected (68.6%), and also showed a higher recurrence rate (42.9%) compared to their male counterparts (18.8%). The median age at diagnosis was 37.5 years, with 72% of patients below age 50. Blacks were more commonly affected (39.2%), followed by Hispanics (23.5%) and Caucasians (21.6%). The latter showed the lowest rate of recurrence. The abdominal wall was most frequently affected (30.8%), followed by mesentery (13.5%) and upper extremities (13.5%). Tumors located in the upper extremities showed a markedly increased rate of recurrence, as well as those with positive and unknown surgical margin status (35 and 45%, respectively). Four patients developed different primary neoplasms during follow-up and two patients had separate metachronous fi bromatoses. One patient had a prior diagnosis of adenomatous polyposis of the colon. 32 patients underwent imaging studies prior to surgery. The majority received a CT scan as the initial imaging modality (68.5%), followed by MRI (21.8%). The most common radiologic diagnosis was unspecifi ed mass/neoplasm (31.3%), followed by sarcoma (28.1%), hematoma (21.8%) and desmoid-type fi bromatosis (21.8%). Conclusions: In our cohort, desmoids were observed most commonly in women and patients below age 50. Lesions occurring in women, in the upper extremities or with positive surgical margins showed a higher rate of recurrence. Radiologic diagnosis was often nonspecifi c. A larger study is necessary to better determine relative risk for recurrence.
The Expression of STAT6 in Mesenchymal Tumors: An Immunohistochemical Study with an Emphasis on the Morphological Spectrum of Solitary Fibrous Tumor
A Matsuyama, T Kasai, R Shibuya, E Shiba, M Nakamoto, M Hisaoka. University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan. Background: The soft tissue tumors previously designated by Stout as hemangiopericytoma (HPC) have been classifi ed into several categories of tumors including solitary fi brous tumor (SFT), and the term "HPC" has been preserved only in HPC of central nervous system (CNS) and sinonasal-type HPC in the recent WHO classifi cations of tumors. In 2013, solitary fi brous tumor has been demonstrated to constantly harbor the NAB2-STAT6 fusion gene. The subsequent immunohistochemical and molecular study showed that SFT and HPC of CNS share the fusion gene and thus they are considered to constitute variants of a single tumor entity. It is recommended to re-evaluate the histological spectrum of SFTs by detection of the STAT6 rearrangement in soft tissue tumors including sinonasal-type HPC. Design: We examined immunohistochemical expression of STAT6 in 400 mesenchymal tumors including 29 SFTs (2 fat-forming type, 3 giant cell angiofi broma and 3 malignant), 2 sinonasal-type HPC and 4 myopericytomas. Only intranuclear staining was considered to be positive. Results: Immunohistochemically, 24/29 STFs were diffusely and intensely positive for STAT6. STAT6-negative SFTs included 2 fat-forming types, 2 giant cell angiofi bromas and 1 mitotically active SFT. STAT6 was also expressed in 1 myopericytoma, which focally showed characteristic concentric growth of tumor cells and was diffusely immunoreactive to actins but negative for h-caldesmon. STAT6 was only focally and weakly stained in other 5 tumors (2/25 spindle cell lipomas, 2/28 nodular fasciitis, 1/7 low grade fi bromyxoid sarcoma). On the other hand, the other tumors including tumors simulating SFT or with a hemangiopericytomatous appearance such as angiomyofi broblastoma, cellular angiofi broma, myofi broma and sinonasal-type HPCs were all negative for STAT6. Conclusions: Our study suggests that STAT6 is a useful immunohistochemical marker for a diagnosis of SFT. Histological variants of SFT include giant cell fi broblastoma, and fat-forming SFT and sinonasal-type HPC may be distinctive entities of tumors based on the status of the STAT6 expression. A subset of SFT and myopericytoma may share the morphological and immunohistochemical features including a characteristic concentric growth of actin-positive myoid cells. Background: Solitary fi brous tumor (SFT) is an uncommon mesenchymal neoplasm of probable fi broblastic origin with widespread anatomic distribution which can be diffi cult to diagnose in limited samples. We recently encountered a diagnostically challenging fi ne needle aspirate of a pancreatic mass, which was initially incorrectly diagnosed as metastatic renal cell carcinoma based on strong PAX8 expression by immunohistochemistry (IHC). After Whipple resection, morphologic features along with additional IHC (CD34 positivity) identifi ed this lesion as a SFT. PAX8 and PAX2 are transcription factors commonly used as markers of primary and metastatic renal and Mullerian malignancies. To date, no series has investigated the prevalence of PAX8 or PAX2 expression in SFT. Design: IHC for PAX8 (Cell Marque) and PAX2 (Invitrogen) was performed on from 37 biopsy and resection specimens of SFT from the pleura and thorax (n=12), head and neck (n=20), pelvis (n=3), extremities (n=1), and retroperitoneum (n=1). The mean patient age was 55.1years (15 -86). Confi rmatory CD34 staining was present in 21 of 23 cases (93%). Tumors ranged in size from 1.2 to 27 cm. Six tumors were considered histologically malignant and six tumors were recurrences of previously incomplete resections. Staining intensity for both PAX8 and PAX2 (0= no stain, 1+= unequivocal but weak, 2+ moderate, 3+ strong) and extent (<50% of nuclei stained= focal, >50% of nuclei stained= diffuse) was recorded in each case, with only cases that had 2+ or 3+ staining scored as positive. Results: In our cohort, nuclear PAX8 staining was observed at least focally in 29.7% (11 of 37) SFT cases; additionally, nuclear PAX2 staining was positive in 16.7% (6 of 36 cases) SFTs. All cases positive for PAX2 were also positive for PAX-8; while fi ve cases of PAX8 positive SFTs showed no nuclear staining for PAX-2. For both PAX8 and PAX2 positive cases, half (50%) of the cases showed diffuse expression across the tumor, while the other half showed focal expression. We found no correlation between PAX8 and PAX2 positivity and patient age, tumor size, site, cellularity, malignant categorization, or recurrence status. Conclusions: A substantial minority of SFTs demonstrate nuclear expression of PAX8 and PAX2 by IHC, frequently with strong, diffuse expression. These fi ndings present a diagnostic pitfall when evaluating possible metastases from the kidney or gynecologic tract, particularly when the primary tumor shows sarcomatoid or spindle cell morphologies.
A Subset of Solitary Fibrous Tumors Express Nuclear PAX8 and PAX2: A Potential Diagnostic Pitfall
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Osteosarcoma of the Foot: A Review of 15 Cases T Mishra, A Puri, S Desai, B Rekhi, A Gulia, J Bajpai, N Jambhekar. Tata Memorial Hospital, Mumbai, Maharashtra, India. Background: Osteosarcoma (OS) is the commonest primary tumour of the bone, next only to multiple myeloma. The foot is an uncommon site comprising only 0.17-2.08% of all OS. This is a review of 15 OS of foot accrued in the Pathology Department of a tertiary cancer hospital over ten years. Design: Of the 15 cases of OS of the foot between 2003 and 2013, 10 were primarily treated at this hospital, and fi ve were pathology consults. All clinical, radiological and treatment details were abstracted from the charts. All histology material (slides and paraffi n blocks) were re-examined. Results: The 15 cases comprised nine males and six females. The youngest patient was an eight-year old female and the oldest was a 68-year old male (mean age 32 years). All patients had pain and persistent swelling of the affected area, but none had a fracture. The affected bones were calcaneum: 8 cases, talus: 4, metatarsal: 1 and soft tissue: 2 cases. Radiological data was available in 12 cases, of which 11 were reported as either a "primary bone malignancy" or features suggestive of malignancy. In the single exception, the differential was between a chronic fungal infection or an OS. Histologically all cases were conventional high grade OS, of which fi ve were Chondroblastic, three were Osteosclerotic and one was a Giant Cell Rich OS. Nine of the ten patients treated at this hospital received neoadjuvant chemotherapy followed by below knee amputation. The tenth patient had an extraskeletal OS and underwent a wide local excision. Follow-up was available in seven patients (duration 6 to 60 months). Five patients developed metastasis, of which one had metastasis to inguinal lymph nodes at presentation; the remaining developed metastasis to lung and liver, lung, inguinal lymph nodes and lung at 12,15,18 and 25 months respectively after treatment. Conclusions: These 15 cases constituted only 0.62% of all OS accrued in this hospital in a decade. The mean age of foot OS in this study was 32 years, whereas conventional OS mostly affects children and adolescents. Almost half of foot OS affected the calcaneum followed by talus, a fi nding corroborated in literature. In the largest series of foot OS (Mayo clinic), the majority (44 of 52 cases) were high grade, similar to our observation. However, Biscaglia et al (1998) found fi ve of 12 tumors to be low grade. To conclude, primary OS of foot is a rare tumour, which needs to be differentiated from the several more frequent non-osseous lesions affecting the foot.
Immunohistochemical and RT-PCR Analyses of NAB2-STAT6 Fusion Gene Products Reveal Immunodetection of Nuclear STAT6 Protein as a Practical Diagnostic Tool for Solitary Fibrous Tumor T Motoi, I Kato, Y Fukuda, M Ogawa, H Koiwai, S Horiguchi, T Goto, T Hishima. Tokyo Metropolitan Cancer and Infectious Diseases
Center Komagome Hospital, Tokyo, Japan. Background: Solitary fi brous tumor (SFT) is a fi broblastic tumor that occasionally poses diagnostic challenges. Recently, NAB2-STAT6 fusion gene derived from the genomic inversion of 12q13 locus was identifi ed as a constant abnormality of SFTs. In order to utilize the NAB2-STAT6 product as a practical diagnostic tool, we explored its status by using immunohistochemistry and RT-PCR. Design: Fifteen typical SFTs (5 pleural and 10 extrapleural) were immunostained by monoclonal NAB2 and polyclonal STAT6 antibodies. Non-SFT tumors (NTs) that may clinically or histologically mimic SFTs were also examined; they included 16 malignant mesotheliomas, 20 fi broblastic tumors of various types, 5 fi brous histiocytomas (FH), 16 undifferentiated pleomorphic sarcomas (UPS), 17 CD34-positive tumors, 16 miscellaneous spindle cell tumors. The nuclear and cytoplasmic stainings were evaluated separately, and they were scored as 2 ( 50% of tumor cells stained with strong intensity), 1 (5-< 50% stained with any intensity), or 0 (< 5% stained with weak intensity). RT-PCR and direct sequencing were performed using primer sets that were designed to detect previously reported 4 major fusion transcripts. Results: NAB2 was exclusively localized in the nuclei of positive cells, whereas STAT6 was localized in the nuclei and/or the cytoplasms. Score 2 positivity for NAB2 and nuclear STAT6 was observed in all SFTs. None of NTs showed score 2 positivity for nuclear STAT6, while score 2 NAB2 reactivity was also found in NTs (37.8%, 34/90) including 68.8% (11/16) of UPSs and 80% (4/5) of FHs. When the reactivity was categorized into positive (score 2) or negative (score 0 or 1), the sensitivity/specifi city for NAB2 and nuclear STAT6 was 100% /62.2% and 100%/100%, respectively.By RT-PCR, fusion transcripts were detected in 66.7% (10/15) of SFTs, including 7 exon 4-3, 1 exon 6-17, 2 exon 6-18, and 0 exon 7-3 fusion transcripts. Conclusions: Immunohistochemical detection of nuclear STAT6 is the most reliable and practical adjunct for diagnosing SFTs because of a fairly consistent staining pattern regardless of the tumor sites, histology, and fusion transcript subtypes. Concomitant nuclear overexpression of NAB2 and STAT6 presumably indicates the fusion gene products. By contrast, the fusion transcripts were detectable by RT-PCR in only a limited number likely due to the variety in exon combinations.
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Impacts of a Systematic Histological Review for Desmoid Tumors: About a Series of 735 Cases Reviewed in 42 Months
A Neuville, A-V Decouvelaere, D Ranchere-Vince, P Terrier, F Collin, J-M Coindre.
Institut Bergonie, Bordeaux, France; Centre Léon Bérard, Lyon, France; Institut Gustave Roussy, Villejuif, France; Centre Geoges-François Leclerc, Dijon, France. Background: Desmoid tumors (DT) are rare tumors which are locally aggressive and for which the treatment is changing towards a "wait and see" strategy demanding a fi rm diagnosis on core needle biopsy. Previous publications on DT reported biased series from specialized centers. Design: A national network of pathologists has been set up in France for a systematic review of every new sarcoma, GIST and DT. Moreover, a molecular test is systematically performed for every suspicion of translocation, MDM2 amplifi cation or specifi c mutation for GIST and DT. The following data are collected in a shared database (https://www. rreps.sarcomabcb.org): sex, age, location, depth and size of tumor, date and type of sampling, type and result of molecular test and histotype. Results: From January 1 st 2010 to June 30 th 2013, 735 DT have been collected, representing 4.9% of all registered mesenchymal tumors. They occurred in 478 women and 257 men (mean 44 years, range 1-90, with 31 patients < 15). A previous history of Gardner syndrome was present in 21 cases. Tumor location was abdominal wall (40%), other trunk wall (21%), limbs (15%), intra-abdominal (11%) and other (13% with 24 cases in the breast) in women and intra-abdominal (45%), abdominal wall (12%); other trunk wall (18%), limbs (14%) and others (11%) in men. Type of sampling for the diagnosis has been changed from 22% of core needle biopsies in 2010 to 34% in 2012. Diagnostic discordance has been observed in 20% of cases with 86 false negative and 76 false positive diagnoses of DT. A mutational analysis of CTNNB1 has been performed for 92% of cases and was positive for 79% of cases. Conclusions: This analysis shows the importance of a structured network for the fi nal diagnosis of DT, the feasibility of an almost systematic use of molecular pathology even on core needle biopsies and a more accurate repartition of DT according to the location since the network reviews about 90% of expected cases of sarcomas, GIST and DT in France. Background: Although current therapies have signifi cantly reduced disease-related mortality, recurrent and metastatic osteosarcoma (OS) has a poor prognosis. In this study, comprehensive genomic profi ling of relapsed/metastatic OS samples by next generation sequencing (NGS) was performed to identify genomic-derived drug targets of therapy not tested for in routine clinical practice. Design: Hybridization capture of 3,769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to≥ 50ng of DNA extracted from 42 FFPE samples of OS and sequenced to high, uniform coverage (mean depth 898X) in a CLIA lab (Foundation Medicine). Genomic alterations (base substitutions, small indels, rearrangements, copy number alterations) were determined and then reported for these patient samples. Actionable GA were defi ned as those targeted by anti-cancer drugs on the market or in registered clinical trials (CT). Results: There were 17 female and 25 male patients with a median age 32 years (range 9-73 years). There were 4 intermediate grade and 38 high grade tumors. Five OS were Stage II, 3 were stage III and 34 were Stage IV at time of sequencing. Twenty six (23 from bone, 3 from soft tissue,) were primary tumors and 16 were metastases biopsies. A total of 130 GA were identifi ed in 36/42 (86%) with an average of 3.1 GA per tumor. The most common non-actionable GA were mutations in TP53 (38%), RB1 (21%), and DNMT3A (7%) and amp in MYC (21%). Twenty eight (67%) OS harbored at least 1 actionable GA with an average of 1.62 actionable GA per patient including: mutation/ homozygous deletion in CDKN2A/B (24%) PTEN (10%) and PIK3CA (7%); amp in PDGFRA (14%), MCL1 (14%), KIT (12%), KDR (12%), CCNE1 (12%) CDK4 (5%), and MET (5%). A long tail of actionable alterations in a single case included: BRCA2, CCND1, CCND2, FGFR1, GNAS, FBXW7, MAP2K2, MDM2, PTCH1, RAD50, RICTOR and TSC1. Conclusions: Two-thirds of OS harbored actionable GA which has the potential to infl uence and personalize therapy selection. The diverse list of altered genes and involved genomic pathways indicate that a broad diagnostic assay is needed to maximize targeted therapeutic options for each OS patient. Thus, given the limited current treatment options for patients with metastatic OS, comprehensive NGS-based genomic profi ling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease. . A comparison study between 9,200 patients treated at Beijing Ji Shui Tan Hospital (JST) and 11,839 patients treated at Mayo Clinic (MC), Rochester MN, US was conducted to identify any potential epidemiological differences. The patients' age and sex, the tumors' site and histologic diagnosis were analyzed. Statistical analysis was performed with the SPSS software (version 20.0; IBM). Results: Giant cell tumor and osteosarcoma had signifi cantly higher incidences in the JST than the Mayo Clinic patients (P<0.001). However, JST patients had a signifi cantly lower incidence of Ewing sarcoma, chordoma, fi brosarcoma, myeloma, and malignant lymphoma (P<0.001). For most benign and malignant bone tumors, the Chinese cohort showed a more distinct male predominance than the US cohort. In the JST patients, malignant bone tumors demonstrated a mono-modal age distribution with the peak incidence in the second decade of life (36.6%), while a bimodal age distribution in the MC cohort with an initial peak in the second decade of life (21.0%) and second peak between the fi fth and seventh decades of life. Predilection to femur and tibia was also found in the JST patients (P<0.001). Conclusions: This is the fi rst study demonstrating the epidemiological differences of primary bone tumors between the largest Chinese and US cohorts. The result may guide future studies to better understand the contributing genetic and enviromental factors of these tumors. However, most epigenetic studies of Ewing's sarcoma have focused on the analysis ofonly a few candidate genes and comprehensive studies were thus lacking and necessary. The aim of this study was to identify novel methylation markers in Ewing's sarcoma using microarray analysis. Design: We report herein the microarray-based DNA methylation study of 1,505 CpG sites of cancer-related 807 genes from 69 Ewing's sarcoma samples. We used Illumina'sGoldenGate Methylation Cancer Panel I microarray.Using appropriate controls (n=14), we identifi ed a total of 92 hypermethylatedgenes in the Ewing's sarcoma samples. Results: Most of the hypermethylated genes were related to cell adhesion, cell regulation, development and signal transduction.We compared overall methylation meansbetween patients who survived and those who did not. The overall methylation mean was signifi cantly higher in patients who did not survive(0.25 ± 0.03) than in those who did (0.22 ± 0.05) (p=0.0322). However, the overall methylation meandid not signifi cantly correlate with age, sexand tumor location. GDF10, OSM, APC and HOXA11 were the most signifi cant differentially methylated genes but their methylation levelsdid not signifi cantly correlate with the survival rate.
Comprehensive Genomic Evaluation of Osteosarcoma with a Targeted Next Generation Sequencing Assay Reveals Frequent Actionable Genomic Abnormalities and Potential New Routes to Targeted Therapies
Conclusions:
We characterized the DNA methylation profi le of Ewing's sarcomas and detected92 genes that were signifi cantly hypermethylated. A trend toward more aggressive behavior was identifi ed in the methylated group. The results of this study suggest that methylation may play an important role in the development of Ewing's sarcomas. Background: Chemokines are a family of peptide mediators that play an essential role in cellular migration and intracellular communication in tumor cells as well as immune cells. We hypothesized that the CXCL16-CXCR6 ligand-receptor system plays an important role in Ewing sarcoma family tumor (ESFT) progression. Design: Using real time quantitative reverse transcription-polymerase chain reaction, we investigated the mRNA expression of CXCL16, CXCR6 and ADAM10 in various cell lines. We also investigated the expression of CXCL16, CXCR6, ADAM10 and ADAM17 in tissue samples from 61 ESFT patients using immunohistochemistry. Results: The mRNA expression levels of CXCL16 and CXCR6 in the ES cell line were higher than those in the other cell lines.
CXCL16 and CXCR6 in Ewing Sarcoma Family Tumor
Immunohistochemical staining revealed that CXCL16 and CXCR6 were highly expressed in tumor cells of ESFT and showed a positive correlation between them. The expression of CXCL16 and CXCR6 was associated with the occurrence of lung metastasis. Univariate analysis revealed that CXCL16 or CXCR6 expression was associated with worse prognosis of ESFT patients.
In addition, CXCL16 and CXCR6 expression was associated with shorter overall survival irrespective of other prognostic factors. Conclusions: Our results suggest that CXCL16/CXCR6 axis appears to be important in the progression of ESFT, resulting in more aggressive clinical behavior. Furthermore, there may be a decrease in the overall survival in ESFT patients who have tumors that stain strongly for CXCL16 and CXCR6.
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Immunohistochemical Analysis of HMGA2 Expression Fails to Provide Evidence of a Neoplastic Basis for "Primary" Synovial Lipomatosis DR Olson, JT Schowinsky. University of Colorado Denver School of Medicine, Aurora, CO. Background: Synovial lipomatosis is characterized histologically by villous proliferation of the synovium with expansion and often replacement by mature adipocytes, occasional mild to moderate chronic infl ammation, and variable synovial hyperplasia and fi brosis. Clinicopathologically, synovial lipomatosis is divided into primary disease, also known as lipoma arborescens, where the lipomatosis is the predominant pathologic feature in the joint, and secondary disease, where the lipomatosis is deemed to arise as a reaction to pre-existent joint disease, typically osteoarthritis. While some have proposed primary synovial lipomatosis to be a non-neoplastic reactive condition, it has traditionally been viewed as a variant lipomatous neoplasm, and gross and microscopic pictures of synovial lipomatosis are present in the lipoma chapter of the most recent WHO Classifi cation of Tumours of Soft Tissue and Bone. Overexpression of HMGA2 is known to be detectable by immunohistochemistry in up to 86% of conventional lipomas, but to our knowledge has not yet been explored in synovial lipomatosis. Design: The available surgical pathology archives of our institution (spanning 10 years) were searched for cases with the words "synovium" or "synovial" and the words "lipoma" or "lipomatosis," as well as for the phrase "lipoma arborescens." All returned cases were reviewed, and all cases clinically and histologically consistent with primary synovial lipomatosis (n=5) or with features indeterminate between primary and secondary synovial lipomatosis (n=3) were included in the study. In addition, 9 cases most consistent with secondary synovial lipomatosis (most refl ecting incidental histologic fi ndings on review of routine joint replacement specimens) were included, as well as 4 cases of conventional lipoma, and 4 samples of benign adipose tissue. Selected cases underwent immunohistochemical evaluation with a monoclonal anti-HMGA2 antibody.
Results: All cases of synovial lipomatosis, regardless of classifi cation as primary, indeterminate, or secondary, were negative for overexpression of HMGA2. 3 of 4 conventional lipomas were positive for overexpression of HMGA2, and all samples of benign adipose tissue were negative. Conclusions: The fi ndings support the growing hypothesis that synovial lipomatosis, including "primary" cases where the lipomatosis is the predominant pathologic fi nding in the joint, is a reactive non-neoplastic process. Background: Epithelioid Hemangioendothelioma (EHE) is a lower-grade malignant vascular neoplasm that may be diffi cult to diagnose due to morphologic features reminiscent of both epithelial and mesenchymal tumors. Recently, two subsets have been identifi ed by translocations resulting in the WWTR1/CAMTA1 and YAP1/TFE3 fusion genes. We sought to develop molecular and immunohistochemical (IHC) assays to aid in the diagnosis and molecular characterization of these tumors. Design: 62 formalin-fi xed, paraffi n-embedded (FFPE) cases of EHE diagnosed between 2001 and 2013 were retrieved from the pathology fi les of our institutions. Ages at presentation ranged from 12 to 78 (median: 46) years, with a male: female ratio of 33:29. Locations included: liver, lung, pericardium, skull, and long bones. Multiple primer sets were designed to optimize a RT-PCR assay for the detection of WWTR1/ CAMTA1 fusion transcripts in FFPE tissue. In order to screen for the YAP1/TFE3 fusion gene, TFE3 protein overexpression was examined by IHC. Results: RNA was extracted from 32 cases, with more recent cases providing a greater yield of high quality RNA. 8 of 10 (80%) informative cases were positive for WWTR1/CAMTA1 fusion transcripts by RT-PCR, one of which showed malignant features. Previously undescribed in-frame fusion transcripts were identifi ed in 3 cases by Sanger sequencing. In one case, new fusion sites within exon 3 of WWTR1 and exon 9 of CAMTA1 were identifi ed. Two cases demonstrated fusion of WWTR1 exon 2 and portions of intron 2 to new sites within exon 9 of CAMTA1. IHC revealed variable nuclear staining for TFE3 in 9 of 24 cases; three with patchy staining were found to have the WWTR1/CAMTA1 fusion transcript. Conclusions: RT-PCR for WWTR1/CAMTA1 fusion transcript detection can be applied to clinical FFPE specimens to support the diagnosis of EHE; and fusion transcripts can be identifi ed in cases with malignant features. We demonstrate additional structural complexity in WWTR1/CAMTA1 fusion transcripts. Initial results suggest that IHC for TFE3 is not entirely specifi c and further molecular testing is recommended. Molecular testing of additional cases, including identifi cation of YAP1/TFE3 fusion, is currently on-going. 
M o l e c u l a r C h a r a c t e r i z a t i o n o f E p i t h e l i o i d Hemangioendotheliomas Identifies Novel Variants of WWTR1/CAMTA1 Fusion Transcripts
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CIC-Rearranged Pediatric Sarcomas Associated with Novel Translocations and Unusual Clinical Presentations
Background:
The accurate classifi cation of pediatric primitive sarcomas has remained challenging. Some of these cases have recently been shown to harbor recurrent translocations involving the CIC gene, such as t(4;19) and t(10;19). In this study, we sought to identify additional pediatric cases to characterize their genetic alterations, as well as their histopathology and clinical characteristics. Design: We searched the pathology fi les of our institution for primitive sarcomas confi rmed to be negative for sarcoma-associated translocations. 26 cases diagnosed from 2001 to 2012 were identifi ed and 8 unique patient samples with a small blue round cell morphology were retrieved. FISH analysis was performed using a dualcolor interphase break-apart probe for the 5' and 3' regions of the CIC gene. Complete karyotypes were available in 6 cases. Results: 5 of 7 cases showed CIC-rearrangements by FISH; one case could not be interpreted due to poor preservation. Patients with CIC-rearranged tumors showed a male: female ratio of 4:1 and mean age of 14.8 years at diagnosis. Primary lesions involved the liver, right hemithorax, pelvic soft tissue, and thigh, measuring from 3.5 to 28.9 cm. 3 cases showed multifocal disease at presentation. Histologically, they consisted of sheets of primitive round cells with occasional prominent nucleoli, focal spindle cells, geographic necrosis, and brisk mitotic activity. Immunohistochemical staining for CD99 was variably positive in a cytoplasmic or membranous pattern. One patient presented with a large liver mass encasing the colon and a diaphragmatic implant, and had a complex tumor karyotype with t(X;19),+8,+12,+20; this patient is free of disease 3 years post-resection, chemotherapy and radiation. A second patient presenting with multifocal involvement of the scrotum and inguinal soft tissue-and a tumor carrying a t(4;19;6),+8 with a subclone harboring a t(X;5) translocation-developed recurrence post-chemotherapy and resection with subsequent death. A third patient presenting with a 28.9 cm thigh mass and metastases to the lung and lymph nodes also showed chemoresistance and died despite therapy. Conclusions: CIC-rearranged Primitive Sarcomas are clinically aggressive and, thus, critical to recognize. We identifi ed additional pediatric cases showing a wide clinical spectrum and novel cytogenetic fi ndings associated with the CIC rearrangement, in addition to trisomy 8. Molecular studies are currently being performed to further characterize the variant translocations and fusion transcripts.
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The BCOR/CCNB3 Fusion Gene Is Present in a Subset of Undifferentiated Pediatric Sarcomas TL Peters, V Kumar, D Lopez-Terrada, A Roy. Texas Children's Hospital, Houston, TX; Baylor College of Medicine, Houston, TX. Background: The BCOR/CCNB3 fusion gene, resulting from a chromosome X paracentric inversion, was recently described in 4% of bone sarcomas with "Ewing's-like" features. Here, we investigated the prevalence of this fusion gene in undifferentiated/unclassifi ed childhood sarcomas, a group of tumors lacking defi ning morphological features or markers. Design: An institutional database was searched over a 10-year period to retrieve archived cases of undifferentiated sarcoma, small round cell tumor, peripheral primitive neuroectodermal tumor and/or Ewing sarcoma-like tumor, excluding cases with characteristic fusion genes or translocations detected by RT-PCR, FISH and/or cytogenetics. Three Ewing sarcomas with documented EWSR1 rearrangement served as negative controls. A RT-PCR assay was designed to amplify the BCOR/CCNB3 fusion from formalin-fi xed paraffi n-embedded and fresh-frozen tissue, with primers on BCOR exon 15 and CCNB3 exon 5. Long-range PCR and primer walking were used to map genomic breakpoints. CCNB3 expression was evaluated using a commercially available antibody. Results: Twelve samples (3 bone, 9 soft tissue) from twelve unique patients (ages 1-17 years; M:F=2:1) were tested. RT-PCR on RNA from FFPE tissue revealed 3 cases with robust amplifi cation of a 171-bp product with sequencing revealing an in-frame fusion of BCOR exon 15 and CCNB3 exon 5 (3/12=25%) that resulted from cryptic splice site activation in BCOR and skipping of the stop codon. The genomic breakpoint in each case mapped to unique sites within CCNB3 intron 4. All three cases were soft tissue tumors in male patients demonstrating both large pleomorphic round cells and areas of spindled cells with brisk mitotic activity, expressing vimentin and variable CD99. Tumor cells had prominent nuclear expression of CCNB3. The fusion was detected in multiple recurrences and metastatic lesions in two positive patients who succumbed to disease. Conclusions: This study expands the clinical and morphological spectrum of BCOR/ CCNB3-positive sarcomas. In our series of undifferentiated/unclassifi ed sarcomas, fusion-positive lesions were soft tissue tumors with undifferentiated round and spindle cell morphology. Molecular techniques unambiguously identifi ed fusion junctions providing a useful aid for diagnosis. The BCOR/CCNB3 oncoprotein may drive tumorigenesis through aberrant cell cycle regulation. Further studies will shed light on the pathobiology of these tumors.
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Human Cytomegalovirus Is Present in Alveolar Soft Part Sarcoma RL Price, H Kurt, L Harkins, AE Chiocca, PZ Zhang, OH Iwenofu. The Ohio State University, Columbus, OH; Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA; Hospital of the University of Pennsylvania, Philadelphia, PA. Background: Alveolar Soft Part Sarcoma (ASPS) is an exquisitely rare sarcoma of unknown histogenesis, with a predilection for adolescents and young adults, characterized by slow progressive clinical course and high frequency of metastases. These tumors are often chemoresistant, thus surgery remains the mainstay of therapy with very limited treatment options in the metastatic setting. Human cytomegalovirus (HCMV) is a DNA -herpes virus and like all herpes viruses, it is characterized by persistent lifelong and latent infection. There is growing evidence to indicate the presence of HCMV proteins and nucleic acids in glioblastoma multiforme (GBM), medulloblastoma and a variety of solid organ malignancies of the breast, prostate, lung and colon at very high prevalence. Immunotherapy based clinical trials targeting specifi c CMV proteins are currently in progress in the treatment of GBM. Herein, we evaluated for the presence of HCMV proteins (IE1 and pp65), genes (US28 and UL96) and RNA by immunohistochemistry (IHC), DNA polymerase chain reaction (PCR), and in situ hybridization respectively in a cohort of ASPS. Design: 6 confirmed cases of ASPS were retrieved from the archives of the Departments of Pathology at OSUMC and the University of Pennsylvania. Full thickness sections of formalin fi xed paraffi n embedded material were stained for anti-HMCV-IE1 and anti-HCMV-pp65. Any nuclear and/or cytoplasmic staining was considered positive. DNA was purifi ed from 50μ of FFPE material. One hundred ng of DNA was amplifi ed using PCR for primers specifi c to HCMV-US28 (forward: AGCGTGCCGTGTACGTTAC, and reverse: ATAAAGACAAGCACGACC) and HCMV-UL96 (forward: ACAGCTCTTAAAGGACGTGATGCG, reverse: ACCGTGTCCTTCAGCTCGGTTAAA) using Promega (Madison, WI) Taq polymerase according to manufacturer's protocol. HCMV in situ hybridization (ISH) was performed. Results: All 6 cases of ASPS were positive for both HCMV-IE1 and HCMV-pp65 by IHC. Usable DNA was available in 4 of the 6 cases. DNA from the HCMV-US28 gene was found in 75% (3/4) of cases and HCMV-UL96 gene was detected in 50% (2/4) of cases. Importantly, all cases tested positive for at least one gene. 3/4 cases were positive for HCMV by ISH. Conclusions: This is the fi rst study to detect HCMV in ASPS. The presence of HCMV DNA, RNA along with HCMV protein indicates that HCMV is present in ASPS and may contribute to it's pathogenesis and provide a basis for targeted immunotherapy.
BCOR-CCNB3 Sarcoma: A Single Institution Experience of 8 Cases
Background: BCOR-CCNB3 fusion transcripts were recently identifi ed in a series of undifferentiated small cell sarcomas with Ewing's-like features. BCOR-CCNB3 sarcoma appears to be rare: to date only a single case series has been published. To further characterize its morphological features and clinical course as well as diagnostic tools for its recognition, we report our experience of 8 cases of BCOR-CCNB3 sarcoma.
Design: Undifferentiated small cell sarcomas without Ewing's sarcoma associated transcripts and monotonous morphology with small to medium cell size were immunohistochemically stained for CCNB3. RNA was extracted from formalin-fi xed paraffi n-embedded and freshly frozen tumor material if available. BCOR-CCNB3 fusion transcripts were identifi ed by RT-PCR and confi rmed by Sanger sequencing. Clinical follow up was obtained. Results: 8 sarcomas that harbor BCOR-CCNB3 transcripts were identified among 92 cases of undifferentiated sarcomas with no or unknown transcripts. Immunohistochemistry showed nuclear positivity in all BCOR-CCNB3 cases, but also showed non-specifi c staining in cytoplasm and in necrotic areas of BCOR-CCNB3 negative sarcomas. On mRNA level all cases showed identical break-points. All cases showed discohesive small, plump to slightly spindle cell morphology with angulated nuclei lying within an edematous matrix. 7 of 8 patients were male. The age range was 13 to 18 years). 5 tumors were primarily located in bone and 3 in deep soft tissues. 3 occurred in the axial skeleton or soft tissues, 5 in the appendicular skeleton. 3 patients had metastatic disease at the time of diagnosis (lung x2, osseous x1). All patients were treated according to Ewing's sarcoma protocols. 3 patients died of disease 27, 28 and 110 months after diagnosis, all of whom had tumors located in the axial skeleton, not amenable to curative resection. 3 patients are alive without evidence of disease at 69, 116 and 124 months. 2 patients are currently still receiving treatment. Conclusions: BCOR-CCNB3 sarcomas are rare primitive small cell malignancies occurring in bone as well as in soft tissues. There is a male preponderance and the peak incidence is in the 2nd decade. Immunohistochemistry is a useful tool for screening, however RT-PCR and sequencing should be used for defi nite identifi cation. Correct identifi cation of BCOR-CCNB3 sarcoma appears important for further characterization of this rare sarcoma.
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Histopathological, Immunohistochemical and Molecular Cytogenetic Analysis of 22 Spindle Cell/Sclerosing Rhabdomysarcomas B Rekhi, T Singhvi. Tata Memorial Hospital, Mumbai, Maharashtra, India. Background: As per the current WHO classifi cation of soft tissue tumors, spindle cell and sclerosing rhabdomyosarcoma(RMS), together, have been recognized as another variant of RMS. Design: We evaluated clinicopathological, immunohistochemical(IHC) and molecular cytogenetic features of 22 spindle cell/sclerosing RMSs. Eleven tumors were tested for FISH analysis with RMSI, SPEC t(2; 13) and RMS II, SPEC t(1, 13)dual color fusion probes. Results: Twenty-two tumors in 16 males and 6 females(M: F, 2.6:1), with age ranging from 2-60 years(Mean,21) and size(14 cases), varying from 3-15 cm(Average, 7.9) occurred in head and neck(8)(36.3%),extremities(8)(36.3%),paratesticular region(2) (9%),chest wall(1), abdomen(1),pelvis(1) and paraspinal region(1). Histopathologically, tumors were sclerosing (10)(45.4%), mostly in extremities; spindle cell (8) (36.3%),mostly in head and neck and sclerosing with spindle cell types (4)(18.1%). Tumor cells, including rhabdomyoblasts(7 tumors) were variably arranged, especially sclerosing RMSs in pseudovascular, focal embryonal(5 cases) and alveolar(3 cases) patterns;with their cells embedded in hyaline and/ or pseudochondroid matrix. Overall, immunohistochemically, tumor cells were positive for desmin(22/22)(100%), MyoD1(mostly diffuse)(19/19)(100%), myogenin(focal)(14/16)(87.5%), SMA(mostly weak)(2/3) and MIC2(weakly cytoplasmic)(2/8)(25%). On FISH analysis, only a single tumor exhibited RMS1 fusion.
Nineteen patients underwent surgical resection and were offered adjuvant chemotherapy(CT)(5 cases), adjuvant radiotherapy(1 case) and adjuvant CT+RT(4 cases); 2 patients underwentCT and 1 patient underwentCT+RT. On follow-up(17 cases)(2-36 months), 6 tumors recurred and 10 metastasized, mostly to lungs. Finally, 13 patients were alive-with-disease(2-36 months), 3 were free-of-disease(6-12 months) and a single patient died-of-disease(16 months). Conclusions: Spindle/sclerosing RMSs are aggressive tumors with proclivity for head and neck and extremities. Spindle and sclerosing RMSs are histopathologically related, considering certain tumors exhibit both patterns. IHC and molecular cytogenetic profi le(to an extent) of these tumors are similar to embryonal RMSs. Rare cases can show histopathological and genetic features similar to alveolar RMS.
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CD105: A Potential Diagnostic and Therapeutic Target for Angiosarcoma W Rizzo, RI Steven, B Darya, F Karen. Mayo Clinic, Rochester, MN; University of Wisconsin, Madison, WI. Background: Angiosarcoma may present a diagnostic challenge in poorly differentiated cases. Although several markers of endothelial differentiation are available, their sensitivities vary, and it is not uncommon to encounter an angiosarcoma which is negative for one or more of these. Additionally the therapeutic options for angiosarcoma are limited. Endoglin/CD105 is a homodimeric transmembrane glycoprotein expressed on the surface of endothelial cells, and there is evidence that anti-CD105 antibodies bind preferentially to activated endothelial cells. In this study, we investigated the value of anti-CD105 antibodies in the diagnosis of angiosarcoma. We also explored the expression of CD105 in non-neoplastic blood vessels in tumor and peri-tumoral tissue in angiosarcoma to evaluate CD105 as a potential therapeutic target. Design: Immunohistochemistry for CD105 (Leica Biosystems) for was performed on 146 sarcomas and 12 benign vascular proliferations from the Mayo Clinic and University of Wisconsin tumor databases including 20 angiosarcomas, 19 chondrosarcomas, 7 Ewing sarcomas, 20 osteosarcomas, 40 leiomyosarcomas (LMS) (20 gynecologic, 20 non-gynecologic), 20 synovial sarcomas, 20 undifferentiated pleomorphic sarcomas and 12 hemangiomas. Following verifi cation of diagnosis, either cytoplasmic or membranous expression was scored semi-quantitatively as 0 (<5% cells staining), 1+ (5-24%), 2+ (25-49%), and 3+ (50%). Tumors with scores of 2+ and 3+ were considered positive. Intra-tumoral and peri-tumoral non-neoplastic blood vessels in cases of angiosarcomas were qualitatively evaluated as positive or negative. Conclusions: CD105 is a sensitive (80%) and specifi c (90%) marker for angiosarcoma and may be helpful in poorly differentiated cases to confi rm lineage. CD105 is a potential therapeutic target as it is expressed in both lesional cells and associated non-neoplastic vessels. Background: V600E BRAF mutation occurs very rarely in GISTs (5-20% of KIT/ PDGFRA wild type GISTs) and acts as a mechanism alternative to KIT/PDGFRA mutation. The performance of BRAF-V600E specifi c antibody (VE1) has been analyzed on a variety of tumors, with heterogeneous results. Our goal was to test the utility of this antibody in GISTs. Design: A fi rst set of 25 GISTs on freshly cut whole section with 5 BRAF-mutated and 20 BRAF WT cases (16 KIT and 4 PDGFRA-mutated) and a second set of 230 GISTs on tissue microarray (TMA), including 2 BRAF-mutated cases and 228 control cases (152 KIT, 52 PDGFRA mutated and 24 KIT/PDGFRA/BRAF WT cases) were immunostained (clone VE1, Spring Bioscience, Pleasanton, CA) by an automated immunostainer (Dako Autostainer, DakoCytomation, Glostrup, Denmark). In order to optimize the method, a range of conditions were tested (pH6 and pH9 buffer; 1:25, 1:50, 1:100 dilutions) and pH9 and 1:100 were used. Cases without staining or with a very faint staining barely perceptible at high power were considered as negative. Cases with a cytoplasmic staining were considered positive and scored as weak, moderate and strong. Results: Of the fi rst set, the 5 BRAF-mutated GISTs were VE1 positive (2 weak, 1 moderate, 2 strong), with a diffuse staining in 4 cases and focal in 1. The 20 BRAF-WT cases were negative. Of the second set, the 2 BRAF-mutated cases were VE1 positive (1 weak and 1 moderate).and, among the control cases, 209 (91,7%) were negative, whereas 19 (8,3%) cases were weakly positive. In the latter subset KIT/PDGFRA-mutated VE1 positive cases, co-existence of KIT/PDGFRA and V600E BRAF mutation was ruled out by subsequent BRAF sequencing. Conclusions: Overall the concordance rate between immunohistochemistry and molecular analysis was 92,5%, with VE1 sensitivy of 100% and specifi city of 92,3%. Notably, 3/7 BRAF-mutated GISTs showed a weak VE1 staining as well as a subgroup of control GISTs. Thus, in order to confi rm the presence of V600E mutation, GISTs with weak VE1 expression should be sequenced.
BRAF-Mutated GISTs: Immunohistochemistry Versus Molecular Analysis
S Rossi, M Cacciatore, D Gasparotto, L Toffolatti, V Carraro, G Gallina, E Scaramel, E Boscato, M
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Aggressive Angiomyxoma (AAM) of Men and Women: Clinicopathologic Review of 20 Cases AA Salim, D Stockman, J Meis. MD Anderson Cancer Center, Houston, TX. Background: Aggressive angiomyxomas are rare, locally aggressive, mesenchymal fi bromyxoid tumors involving the vulvovaginal, pelvic and perineal regions occurring primarily in women. Aggressiveness in these tumors stems from their diffusely infi ltrative nature and diffi culty in surgical extirpation due to the intricacy of involved anatomic structures. Clinical misdiagnoses as Bartholin or vaginal cysts, lipomas and hernias and a paucicellular banal appearance in core biopsy specimens frequently lead to delayed diagnoses. Design: Twenty patients with AAM were referred to our center over the last 27 years (1986 -2012) . Clinical data and specimens, including biopsies and resections, were reviewed. Results: Tumors occurred in 3 men and 17 women with a median age of 41 years (range, 20 to 86). The tumors ranged from 5.3 to 30 cm (median 12.7 cm) in size, and were distributed as follows: vulva in 2/20 cases (5%), pelvis in 13/20 cases(31%), vagina in 1/20 cases(2%), perineum in 3/20 cases (7%), and retroperitoneum in 1/20 (2%). Histologically, the tumors were comprised of infi ltrative, sparsely populated bland-looking spindled and stellate cells in a fi bromyxoid matrix with admixed small and large blood vessels. By immunohistochemistry, tumors were positive for ER and PR (11) and desmin (9). Clinical follow-up was available in 15 patients with median follow-up of 20 mo (range, 2-307 mo). There were recurrences in 6/20 cases (30%); median interval to recurrence was 13 months (range 5-307 mos). Conclusions: Aggressive angiomyxoma is a potentially aggressive, non-metastasizing soft tissue tumor occurring in both men and women. Defi nitive diagnosis in core biopsy specimens is particularly diffi cult when fatty infi ltration is not present, small vessels are not numerous, or entrapped smooth muscle is seen. Large caliber vessels are often prominent in resection specimens as are less myxoid zones that may overlap or cause confusion with angiomyofi broblastoma. Cases occurring in males have a less prominent fatty component.
96
Clinical Results: Out of these 133 tumors, 20 (15%) had TP53 mutations, 3 (2%) had IDH1 mutations, 3 (2%) had BRAF mutations, 2 (1%) had ATM mutations, and 2 (1%) had APC mutations. Eight genes showed mutations in one case each (RB1, PTEN, NRAS, KRAS, GNAS, FGFR1, ERBB4 and CDKN2A) , while 102 cases (76%) showed no somatic mutations by this targeted panel. Mutational prevalences varied amongst sarcomas types. For instance, TP53 mutations were very rare in Ewing sarcoma/PNET (2 of 29 cases), but relatively common in unclassifi ed sarcomas (9 of 34 cases). Of note, fi ve tumors showed more than one mutation: chondrosarcoma (1 case), dedifferentiated chondrosarcoma (1), rhabdomyosarcoma (1) and unclassifi ed sarcoma (2). Conclusions: Our study shows that mutation rates are relatively low amongst sarcomas. However, this may be due to the use of a panel optimized for mutational events in non-mesenchymal tumors. As the genomic features of sarcomas are better defi ned, it is anticipated that NGS panels more appropriate to sarcomas can be developed. All tumors showed prominent areas with myxoid morphology, comprising 60 to 100% of the entire tumor. Histiocytoid tumor cells exhibited oval or polygonal vesicular nuclei, inconspicuous nucleoli, and palely eosinophilic cytoplasm with ill-defi ned borders. Typical multinodular growth was observed with whorls or loose trabeculae of tumor cells in hypocellular areas with prominent myxoid matrix and occasional transition to more solid nodules. Mucin pools and scattered multinucleate giant cells were observed in a subset of cases. Mitoses were scant and no necrosis was present. Mild to moderate atypia was observed in 4 cases; 1 tumor showed rhabdoid features. Tumor cells expressed EMA (11/20), desmin (13/20), CD99 (2/3), and CD68 (2/6). FISH was performed in 7 tumors and revealed EWSR1 rearrangement in 4 cases. Five tumors were excised with a suspected diagnosis of sarcoma; 1 patient received preoperative radiotherapy. Followup data, available for 9 cases (median, 40 months), revealed that 3 patients developed local recurrence after 2, 7, and 48 months, respectively. All patients were alive without evidence of disease and none have developed metastases. Conclusions: AMFH may rarely present with a prominent myxoid matrix, making diagnosis more diffi cult and causing possible confusion with other myxoid tumors such as extraskeletal myxoid chondrosarcoma, myoepithelial tumors, and low-grade fi bromyxoid sarcoma.
98
Validation of Break Apart FISH Probes for the Detection of COL1A1-PDGFB Rearrangements in Dermatofibrosarcoma Protuberans H-U Schildhaus, E Binot, R Buttner, I Tancheva-Poor, E Wardelmann. University Hospital Cologne, Cologne, Germany; University Hospital Göttingen, Göttingen, Germany; University Hospital Münster, Münster, Germany. Background: Dermatofi brosarcoma protuberans (DFSP) is a malignant mesenchymal tumor of the skin. The underlying molecular mechanisms are various chromosomal rearrangements which result in the formation of a COL1A1-PDGFB fusion gene. Clinically progressive DFSP with these genetic alterations respond to treatment with the tyrosine kinase inhibitor Imatinib. Therefore, the detection of that gene fusion has become one of the rare predictive biomarkers in sarcomas. Traditionally, the COL1A1-PDGFB fusion is determined by RT-PCR or so-called dual color dual fusion FISH probes which cover both involved genes. The aim of our study was to compare different FISH approaches and to validate the most suitable one. Design: A total of fi fty tumors (19 DFSP as well as 21 dermatofi bromas and cellular/ deep penetrating dermatofi bromas) were investigated by using specifi c COL1A1-DFSP dual color dual fusion, COL1A1-PDGFB dual color single fusion, PDGFB break apart and COL1A1 break apart FISH probes. The percentages of aberrant tumor cells were determined for each lesion and each probe set. Results: Two out of eighteen evaluable DFSP (11%) were false negative with the dual color dual fusion probes (but clearly positive for all of the other three probes), indicating that the sensitivity of these probes is comparably low. The dual color single fusion probe approach revealed positive results in 100% of DFSP. However, 14/16 (88%) of all evaluable dermatofi bromas revealed >15% aberrant tumor cells with those probes indicating a high proportion of false positive cases. Best results were achieved with the break apart probes for both genes which resulted in 100% sensitivity and specifi city. Therefore, cut-off levels were determined for the break apart probes statistically (based on the percentages of randomly "aberrant" signals determined in the dermatofi broma cohort).
Conclusions: We could demonstrate that the widely used dual color dual fusion probes do not recognize all types of rearrangements and that nearly 10% of cases will be missed by that approach. Dual color single fusion probes, on the other hand, are often false positive and may result in a misdiagnosis of DFSP, especially in cases of cellular/deep penetrating dermatofi bromas. PDGFB/COL1A1 break apart probes are reliable techniques for the detection of therapeutically relevant COL1A1-PDGFB fusions in DFSP.
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Primary Pulmonary Myxoid Sarcoma Versus Pulmonary Angiomatoid Fibrous Histiocytoma: Cases with Overlapping Features? L Schmidt, SC Smith, N Palanisamy, B Betz, SA Tomlins, R Mehra, DR Lucas, JL Myers. University of Michigan, Ann Arbor, MI. Background: Primary pulmonary myxoid sarcoma (PPMS) is a recently described, potentially malignant lesion showing polygonal and spindled to stellate cells within myxoid stroma. Reported examples show endobronchial growth and a EWSR1-CREB1 fusion in 75% of documented cases. Recent appreciation of an expanded anatomic and morphologic spectrum of angiomatoid fi brous histiocytoma (AFH), which shares the same translocation, raises the possibility that these two might be overlapping entities. Design: We reviewed clinicopathologic features and performed breakapart FISH assays on 3 cases from consultation services at our institution. Results: Three cases of PPMS arose in one woman and two men (Cases A-C, see Table  1 ). All patients underwent lobectomy which showed grossly endobronchial-(A,C) or bronchial-based (B) pale tan-gray glistening nodular to partially encapsulated masses with consolidation of distal lung. All cases showed lobulated to multinodular neoplasms comprising a prominent myxoid stroma containing single epithelioid to spindled/stellate cells arranged individually, in clusters, or in a reticular pattern. AFH-like features included at least focal peritumoral fi brous cuffs (A-C), blood-fi lled spaces (B), and reactivity for desmin (B). Associated infl ammation was mild-moderate and included a prominent lymphplasmacytic infi ltrate in each case. Atypia was prominent in one case (C). Broad-spectrum keratins were negative; focal EMA positivity was present in all cases. EWSR1 rearrangement was present in two (A, B), one of which additionally showed CREB1 rearrangement (A). No rearrangements were detected at the ATF1 locus. All three patients are free of disease. Background: The value of routine histopathologic examination of hip arthroplasty specimens has long been a source of controversy between orthopedic surgeons and histopathologists. For that matter, consensus does not exist as to the appropriate handling of these specimens. The study aimed to quantify the discrepancy rate between clinical and histopathologic diagnosis, and to determine whether microscopic examination of femoral heads is indeed justifi ed. Design: A 13 year retrospective review of 2505 hip arthroplasty specimens was performed at a large tertiary care teaching institution. Clinical diagnosis was compared with fi nal pathologic diagnosis for each case, and major and minor discrepancies were documented. Results: Overall, there was a major discrepancy rate of 2% (48/2505) between the submitted clinical and fi nal pathologic diagnosis. Among these, the highest rate of discrepancy was present in malignant diagnosis [64% (31/48)], followed by osteomyelitis [22% (11/48)]. The cases with major discrepancies were those patients for whom the treatment and/or prognosis was altered following histopathologic diagnosis. Major discrepancies included both clinically unsuspected histopathologic fi ndings and clinical suspicion not confi rmed by microscopic examination (See table 1). In remainder, they were considered minor, with more academic than therapeutic signifi cance (e.g. osteoarthritis versus avascular necrosis of the femoral head). Conclusions: Clinical and histopathologic diagnoses of hip arthroplasty specimens were compared, yielding a relatively low overall discrepancy rate of 2% of all cases harboring major discrepancies. However, the discrepancy rate of malignant diagnosis was fairly high and noted upto 64%, followed by osteomyelitis (22%). These major diagnostic discrepancies signifi cantly altered management and/or long-term prognosis. In our opinion, histopathologic examination of all hip arthroplasty specimens is indeed justifi ed. Future studies to include a larger cohort are suggested to verify these results. Background: ERG gene encodes for an Ets family regulatory transcription factor, and previous studies have shown that ERG immunohistochemistry is relatively specifi c for vascular tumors, among mesenchymal tumors. However, developmental biologic research has also shown ERG to play a role in chondrocyte differentiation and joint formation. We studied ERG expression in a large series of chondrogenic bone and soft tissue tumors to assess the value of ERG as a possible marker of chondroid differentiation. Design: Formalin-fi xed, paraffi n embedded whole sections from 103 bone and soft tissue tumors with chondroid differentiation or a morphology that may mimic cartilaginous differentiation were retrieved from our archives. Immunohistochemistry was performed using mouse anti-ERG monoclonal antibody directed against the N-terminus. Nuclear staining was scored as negative (<5%), 1+ (5-25%), 2+ (26-50%), 3+ (>51%). Any case with at least 1+ staining was considered positive. Only cases with positive internal controls (normal endothelial cells) were scored. Results: All cases of conventional chondrosarcoma (11/11), chondromyxoid fi broma (7/7), chondroblastic osteosarcoma (6/6), and clear cell chondrosarcoma (1/1) were positive for ERG. In cases of dedifferentiated chondrosarcoma, the well differentiated component was positive in 78% (7/9) of cases, while all dedifferentiated foci were negative. In cases of mesenchymal chondrosarcoma, the chondroid component was positive in 100% (3/3) of cases while the primitive component in all cases was negative. Variable positivity was identifi ed in mixed tumors (2/11 positive), extraskeletal myxoid chondrosarcomas (4/9 positive) and chondroblastomas (2/8). Only 1 of 11 cases of chordoma was positive for ERG (1+ staining). Interestingly, 15 of 18 enchondromas were negative for ERG. Conclusions: In this study we have shown relatively constant nuclear ERG expression in selected chondrogenic tumors including conventional chondrosarcoma, chondromyxoid fi broma, chondroblastic osteosarcoma and clear cell chondrosarcoma. While ERG may be a helpful ancillary tool in certain diagnostic scenarios including the differential of conventional chondrosarcoma and chordoma, its utility may be limited as the specifi city recurrences and metastases occur in approximately 50% of cases, usually over a protracted period of time. A relationship to low grade fi bromyxoid sarcoma (LGMFS) has been postulated. Design: Fifteen patients with SEF involving the abdominal cavity and retroperitoneum were identified from the files of a cancer referral center. Clinical, histologic, immunohistochemical and molecular features were analyzed. Results: There were 8 males and 7 females, 19 -79 years of age, who presented with intra-abdominal tumors involving omentum, mesentery, retroperitoneum and/or gastrointestinal tract. Nine cases involved multiple sites, simulating carcinomatosis and 8 were associated with ascites. Tumor sizes ranged from 2 -50 cm (median 17.5 cm). All cases were highly cellular with rounded to oval small cells arranged in nests and cords by delicate to coarse strands of collagen. No areas of LGFMS were seen. EWSR1 gene rearrangement was identifi ed in 4 cases; FUS was not detected in two cases. Follow-up was available in 12 patients ranging from 6 -73 mos (median 14 mos); 7 patients died of disease and 5 were alive with disease at median intervals of 17 and 9 mos, respectively. All patients alive with disease had lung metastases. Conclusions: SEF occurring within the abdominal cavity simulates carcinomatosis and is therefore diffi cult to diagnose both clinically and pathologically. Mesothelioma and GIST must also be excluded as well as unusual presentations of Ewing sarcoma and other small cell malignancies. SEF arising in the abdominal cavity are more aggressive than those arising in the chest wall and extremities. The distinctive clinical presentation, lack of LGFMS-like areas, presence of EWSR1 and lack of FUS gene fusion rearrangements in these cases indicate that "pure" cases of SEF are not a subtype of LGFMS, but rather a distinctive and potentially more aggressive sarcoma.
ERG Expression in Chondrogenic Bone and Soft Tissue Tumors
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Granular Cell Tumors (GCT) of Soft Tissue: A Clinicopathologic Study of 35 Cases J Stone, JA Plaza, S Suster, E Zambrano. Medical College of Wisconsin, Milwaukee, WI. Background: GCTs are benign neoplasms of neurogenic origin commonly arising from superfi cial anatomical locations. Design: GCTs involving deep soft tissues (i.e. +/-deep dermis and below) with no superfi cial dermal/mucosal involvement were selected. Clinical and follow-up data was obtained. HE sections and immunostains including S-100, EMA, CD34, SMA and MOC31 were analyzed in all cases. Results: 35 cases (21 female, 14 male; ages: 5-69 years) were identifi ed: arm (7), chest (7), hand (5), axilla (3), leg (3), foot (2), abdomen (2), scalp (2), cheek (1), vulva (1), back (1), fi nger (1) (size: 1-3.5 cm; median: 2.25 cm). Histologically, 22 tumors had a nodular well-circumscribed appearance, 9 tumors had infi ltrative borders and 4 tumors were multinodular. Tumors were composed of sheets and nests of oval to polygonal cells with abundant, fi nely granular, eosinophilic cytoplasm with well-defi ned cytoplasmic borders, small uniform round to oval nuclei with evenly dispersed chromatin and indistinct nucleoli; 21 cases showed a pure epithelioid appearance, 12 cases showed a mixed epithelioid/spindled appearance and 2 cases had a pure spindle cell appearance. Nine cases showed occasional nuclear pleomorphism; 9 showed perineural invasion and 1 had lymphovascular invasion. Only 2 cases showed rare mitotic fi gures (1 per 10HPF) with no atypical mitoses. No necrosis or hemorrhage was identifi ed in any case. All tumors were strongly positive for S100 protein and negative for all other markers. Follow up from 2 months-4 years revealed only one patient with multiple, multifocal recurrences (35 year-old male; 3 x 2 cm, arm). No atypical histological features, or perineurial or vascular invasion were seen on initial presentation or upon recurrence.
Conclusions:
None of the cases behaved as aggressive malignant neoplasms in spite of their deeper anatomical locations. The presence of occasional atypical features, such as cellular pleomorphism (25.7%), perineurial invasion (25%), mitotic activity (5.7%) and lymphovascular invasion (2.8%), did not infl uence prognosis in these deep-seated tumors.
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Osteomyelitis: Development of a Scoring System Based on Histologic Criteria to Improve Diagnosis in the Foot and Ankle AB Sybenga, D Jupiter, A Rao. Baylor Scott  White Memorial Hospital/Texas AM Health Science Center, Temple, TX. Background: Histopathologic exam of bone specimens is the gold standard of diagnosis for osteomyelitis (OM); however, strict criteria are not widely recognized. Accurate diagnosis of acute OM (AOM) and chronic OM (COM) is important for optimal treatment of patients. We developed a scoring system based on histologic criteria for AOM and COM, and correlated it with clinical follow up of OM in foot and ankle for the 2010 to 2013 period. Design: 750 cases over 3 years were identifi ed. Clinical, radiologic, laboratory and histopathologic fi ndings were collected. From these fi ndings and literature, we developed and weighted 13 histologic criteria to test the feasibility of improving diagnosis of OM. Acute infl ammation, abscess, bacteria, involucrum, and sequestrum are the most supported fi ndings in OM and were assigned a score of 3. Fibrinoid necrosis and marrow fi broplasia, were assigned a score of 2. Nonspecifi c fi ndings, including erosion, remodeling and chronic infl ammation, were assigned a score of 1. A slide review was then performed with strict adherence to the criteria. Also included in the score were radiologic results (2 for AOM, 1 for suspicious for OM (SOM)), and bone culture (1 for positive). Results: A review of previously issued reports indicated 61% utilized descriptive criteria, none of which included complete criteria. 18% of amputations had no margins submitted. Bone cultures were performed in only 14% of cases. The average score for AOM/ACOM was 14.89 with 87% of cases scoring above 11. The average score for COM was 8.95 with 81% scoring between 6 and 11. The average score for no acute OM (NAOM) was 1.94 with 100% scoring 4 or less. No diagnosis of AOM/ACOM scored less than 9, and no diagnosis of COM scored less than 6. COM was diagnosed in 25% of cases, compared to 6% without the scoring system. Clinical follow up results indicate 50% of reamputations and non-healing post-op wounds might have been avoided using our criteria. The criteria were particularly helpful in evaluating margins and fragmented biopsies. Conclusions: Review of reports indicates that current histopathologic criteria for diagnosis of OM is ill defi ned and inconsistently utilized. Our scoring system shows scores greater than 6 are likely OM, scores greater than 11 are likely AOM, and scores less than 4 are NAOM. Bone cultures are infrequently utilized, but seem to correlate more highly with a diagnosis of AOM.
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Quantitative miRNA Expression Profiling as an Objective Tool to Differentiate Malignant Peripheral Nerve Sheath Tumors and Desmoplastic Melanomas SK Tian, PP Koty, OP Sangueza, MG Trizna, SA Qasem. Wake School of Medicine, Winston-Salem, NC; Smithsonian Institute, Washington, DC. Background: Differentiating malignant peripheral nerve sheath tumor (MPNST) from desmoplastic melanoma (DM) can be a diagnostic challenge due to overlapping morphology and immunophenotype. We have recently demonstrated through microarray analysis that miR-138 is differentially expressed and can be used to differentiate these two entities. The aim of this current study is to expand our sample size and confi rm our fi ndings using quantitative polymerase chain reaction (qPCR). Initial global miRNA expression profi ling was performed on archival formalin-fi xed paraffi n-embedded tissue. Then a limited panel of candidate miRNAs was converted to a qPCR format for practicality and economy. Design: A scrreening group of 7 MPNST and 8 DM cases with suffi cient tissue was selected. Each case was independently confi rmed by a soft tissue pathologist and a dermatopathologist. Universal miRNA expression was analyzed with the GeneChip miRNA 3.0 Array (Affymetrix Inc). Data was imported into R software and normalized using the robust multichip algorithm. Differential expression was assessed using the Wilcoxon signed-rank test. Signifi cant human probe sets by microarray were identifi ed based on a signifi cant p-value (<0.05) and a difference of at least ± 1.5 fold-change. Candidate miRNAs demonstrating the most signifi cant difference were selected (miR-138, mir-141, and miR-200a) . A candidate miRNA demonstrating the least variance was selected as a calibrator (miR-892b). Total RNA was used for selective miRNA qPCR (Qiagen Inc). Data was analyzed for relative expression fold change using the 2 - C T method.
Results: MiR-138 demonstrated the most signifi cant relative fold change both on microarray (p=0.02) and qPCR (p=0.006). MiR-141 and miR-200a showed a signifi cant relative difference on the microarray; however, the trend could not be confi rmed with qPCR (see 
Conclusions:
The data supports our previous work suggesting low expression of miR-138 in DM relative to MPNST. A targeted miRNA qPCR multiplex panel can be developed and used, in a clinically meaningful way, as a tool for accurate classifi cation of diagnostically challenging cases. This may also help shed light on the pathobiology of these tumors and any possible therapeutic targets. M Vivero, LA Doyle, CDM Fletcher, F Mertens, JL Hornick. Brigham and Women's Hospital and Harvard Medical School, Boston, MA; University and Regional Laboratories, Skane University Hospital, Lund University, Lund, Sweden. Background: Solitary fi brous tumor (SFT) is a fi broblastic neoplasm characterized by a haphazard growth pattern, bland, spindled cytomorphology, variable amounts of collagenous stroma, and dilated, branching vessels. Individual tumor histology, however, can vary greatly and overlap with other soft tissue tumors, making diagnosis challenging at times. Several existing markers, among which CD34 has been studied most extensively, are used for diagnosis of SFT, but none are specifi c, and all have been shown to stain histologic mimics of SFT. Recent gene expression profi ling studies have revealed marked overexpression of the GRIA2 gene (GluR2), which encodes an AMPA-selective ionotropic glutamate receptor subunit, in SFT. To evaluate the potential diagnostic utility of GRIA2, we examined protein expression in SFT and other soft tissue tumors, including histologic mimics. Design: Paraffi n-embedded whole tissue sections of 375 soft tissue tumors were examined, including 105 solitary fi brous tumors, 20 cases of dermatofi brosarcoma protuberans (DFSP), 9 myoepitheliomas, 20 sarcomatoid mesotheliomas, 20 malignant peripheral nerve sheath tumors, 25 dedifferentiated liposarcomas, 20 monophasic synovial sarcomas, 22 low grade fi bromyxoid sarcomas, 12 spindle cell/sclerosing rhabdomyosarcomas, 10 nodular Kaposi sarcomas, 10 cases of desmoid fi bromatosis, 20 gastrointestinal stromal tumors, 10 cellular schwannomas, 11 deep fi brous histiocytomas, 21 spindle cell lipomas, 10 neurofibromas, and 20 soft tissue perineuriomas. Immunohistochemistry was performed using a rabbit anti-GRIA2 monoclonal antibody (Abcam; EP929Y; 1:100 dilution) following pressure cooker antigen retrieval. Results: In total, 84 of 105 (80%) SFT, including 18 of 21 (86%) malignant SFT and 4 of 4 (100%) dedifferentiated SFT, demonstrated positivity for GRIA2, which was usually moderate or strong in intensity and present in at least 25% of tumor cells. Expression of GRIA2 was also seen in 15 of 20 (75%) DFSP, 4 of 9 (44%) myoepitheliomas, one monophasic synovial sarcoma (<1% of cells), and one cellular schwannoma. No other soft tissue tumors were positive for GRIA2. Conclusions: GRIA2 is a useful diagnostic marker to distinguish SFT from most histologic mimics. Among other CD34-positive tumors, GRIA2 is also positive in most DFSP; however, clinical and histologic features aid in their distinction from SFT. GRIA2 shows a very limited distribution in other soft tissue tumors.
GRIA2 Is a Novel Diagnostic Marker for Solitary Fibrous Tumor Identified through Gene Expression Profiling
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HMGA2 Expression Is Useful in the Diagnosis of Spermatic Cord Fatty Lesions DP Wang, J Schowinsky, JA Wisell. University of Colorado School of Medicine, Aurora, CO. Background: Well differentiated liposarcomas (WDL) of the spermatic cord are rare tumors often found incidentally. These may be diffi cult to recognize and may be misclassifi ed as a 'cord lipoma.' The advent of immunohistochemical (IHC) antibodies against novel antigens has provided a diagnostic tool. IHC antibodies against HMGA2 label a large proportion (up to 86%) of lipomas and WDLs. We postulate that the large majority of 'cord' lipomas are not truly lipomas at all, but rather extensions of nonneoplastic preperitoneal adipose tissue into the inguinal canal; as such, they would not be expected to express HMGA2, furthering the diagnostic utility of this antibody. Design: From our fi les we collected 14 cases diagnosed as 'cord lipoma' and 4 cases diagnosed as lipomas from other locations. We reviewed the morphologic features for all 18 cases. Specifi cally, we assessed cellular size variability, nuclear pleomorphism and nuclear hyperchromasia of the lesional adipocytes and vascular prominence. HMGA2 IHC studies were performed on all 18 cases. Results: All 14 'cord lipoma' cases were entirely negative for HMGA2 and contained large muscular vessels within the lesions. All 4 lipomas from other locations had diffuse and strong HMGA2 labeling. Only one of the lipoma cases contained any large vessels within the lesion. All 18 cases lacked nuclear hyperchromasia and pleomorphism. 3 out of 14 'cord lipomas' and 2 out of 4 lipomas displayed cellular size variation. Conclusions: Our findings support previous anatomic studies that dismiss the longstanding practice of designating fatty deposits within the spermatic cord as 'lipomas.' We found that the presence of muscular vessels within the lesion to be a distinguishing feature of spermatic cord fatty deposits, a feature not typically seen in lipomas. None of the cord lipoma cases exhibited HMGA2 labeling, indicating a different pathogenesis than found in neoplastic adipocytic tumors. In addition to informing the nosology, these fi ndings support the role of HMGA2 as a diagnostic tool when evaluating spermatic cord fatty lesions. unknown. The objective of this project is to retrospectively study available melanotic schwannomas at MSKCC and analyze their genetic characteristics by array-based DNA copy number analysis. Design: Nine cases were identifi ed and in 5 cases FFPE tissue was available for genomic analysis. There were 6 males and 3 females. Median age was 53 years. Tumors were located in chest wall (2), vertebra (2), paraspinal region (2), sacrum (1), ischium (1) and metacarpal bone (1). Tumor size ranged from 2.5 cm to more than 7 cm. Genomic DNAs was extracted from FFPE tumor material and Affymetrix OncoScan SNP-array was used for copy number and allelic imbalance analysis. Results: SNP-array analysis on 5 cases revealed non-random loss of multiple chromosomes, and the most common recurrent abnormalities were loss of chromosomes 1, 2 and 17; other recurrent abnormalities included loss of chromosomes 3 and 21. Allelic imbalance on chromosome 17q was observed in all 5 cases, three of which presented as deletion and two cases showed copy-neutral loss of heterozygosity (CN-LOH) of 17q. It is worth noting that one case showed multiple chromosomal gains rather than loss, however, multiple CN-LOH was also identifi ed in other chromosomes including 1, 2, 3, 17 and 21. Therefore, the combined copy number and allelic imbalance in this case indicate that the genomic abnormalities may result from doubling of a hypodiploid clone. Conclusions: Hypodiploidy is a common genetic feature of Melanotic Schwannoma, and typically involves monosomies of chromosomes 1, 2, and 17. Allelic imbalance on 17q is the single most common aberration observed in this study, which presents as deletion or copy-neutral LOH of 17q. Background: Desmoid fi bromatosis is a benign myofi broblastic proliferation often characterized by mutations in CTNNB1 in sporadic cases. Those associated with germline APC mutations (with familial adenomatous polyposis, FAP) are often multifocal. However, non-FAP related tumors can also rarely be multi-focal either regionally or at distant body sites. We examined a series of such cases and their clinical course. Design: Twenty patients with sporadic multifocal desmoid fi bromatosis (without FAP) were identifi ed from prospective databases at two institutions. Demographics, number of tumors, sites involved, CTNNB1 mutational analysis, and clinical follow-up were tabulated. Results: The median age was 39 (range:15-84) years with slight female predominance (M:F 8:12). Sites of involvement included: trunk (10), extremities (6), chest (4), intra-abdominal (3), head and neck(2) and abdominal wall (1), with 7 patients having multiple tumors at different sites. Number of tumors (n=12) ranged from 2 to 3. Median size (n=14) was 5 cm (range:0.4-24). 12/19 cases developed local recurrence. Follow -up was available in 19 patients: 14 alive with disease, 4 alive and well, and one dead likely from disease. CTNNB1 mutational analysis was available on multiple nodules in four cases: in 2 cases (one extremity and one intra-abdominal) both tumor foci revealed T41A; while two multi-focal intra-abdominal cases show 2 different results for CTNNB1 genotyping (S45P and WT or T41). Conclusions: Patients can rarely have sporadic multifocal desmoid fi bromatosis and interestingly, these tumors can harbor different mutations, arguing that they are separate clonal events. This fi nding raises the possibility that some patients may be prone to develop CTNNB1 mutations.
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Immunohistochemical Study of BRAF V600E Mutant Protein Expression in High-Grade Sarcomas K Whiting, A Valente, J Tull, C Maciak, S Zhang. SUNY Upstate Medical University, Syracuse, NY. Background: V-raf murine sarcoma viral oncogene homolog B1 (BRAF), a serinethreonine protein kinase, is a member of the RAS-REF-MEK-ERK signaling pathway. The BRAF V600E has been considered as a cancer-driving mutation in a variety of neoplasms including melanomas, thyroid carcinomas, gastrointestinal stromal tumors, colorectal carcinomas, ovarian carcinomas and lung cancers. Zalboraf, a FDA approved BRAF V600E kinase inhibitor, has been applied in treatment of melanoma harboring BRAF V600E with considerable response. Although a few studies have been done in sarcomas including Ewing sarcomas and rhabdomyosarcomas, the status of BRAF V600E in high-grade sarcomas remains unclear. In addition, current immunohistochemistry (IHC) with VE1 antibody for BRAF V600E protein is reported highly specifi c and sensitive to predict BRAF V600E DNA mutation, but its utility on high-grade sarcomas is unknown. Design: Forty-eight cases of undifferentiated high grade sarcomas were constructed in duplicate or triplicate cores using tissue microarray technology. IHC with VE1 antibody against BRAF V600E protein (Spring Bioscience, 1:50) was performed as per manufacturer's instructions. The microarrays were independently reviewed by two board-certifi ed pathologists and one pathology resident. IHC staining intensity in cytoplasm was graded from 0 to 3+. 0 and 1+ were considered as negative while 2+ or greater as positive. Selected cases were tested for BRAF V600E gene mutation by real-time PCR for comparison. Results: Forty-one out of 48 specimens remained intact in both cores after IHC processing. Six of the 41 cases (15%) were scored as positive (2+ or 3+) by consensus. These 6 cases were subsequently tested for the BRAF V600E mutation by PCR, and they were all negative. Additionally, weak nuclear staining, which was considered nonspecifi c, was seen in 14% (12/88) of cores examined.
Design: 7 cases of GCT of bone that contain chondroid areas; 6 cases were derived from the consult series of one of the authors and 1 case from University of Miami Hospital. 3 cases had immunohistochemistry (IHC) for S100, 2 had p63, and 1 had EMA available for review. Radiographic information was available for 4 cases, tumor size for 2, and post resection followup for 3. Results: The 7 cases represent a mean age of 24 years (range 8-42), 4 males and 3 females. 4 GCT were located in the distal femur, and the remaining 3 in metatarsal, patella, and scapula. Radiographically, a radiolucent, well circumscribed mass associated with thinning of cortex was present. Tumor size ranged between 4.7 and 6.1 cm. Histologically the tumors contained regions diagnostic of GCT as well as scattered foci of chondroid matrix. The matrix consists of cartilage which is hyaline and fi brocartilaginous in appearance and that in areas appears to be associated with bone. The matrix is surrounded by regions of tumor that have the appearance of GCT and areas where the mononuclear cells have a spindle cell morphology. Minimal necrosis and mitotic activity was observed and no cytologic atypia was observed. By IHC, 2 cases were positive for S100 in chondroid areas when initially diagnosed but were negative when recently repeated. 1 case was negative for S100 in the chondroid areas. In 1 case p63 was positive in the neoplastic mononuclear cells and the cells inhabiting the chondroid areas. EMA was positive in chondroid areas in 1 case. Followup at this time is limited;1 patient is free of disease 5 years after curettage and 2 have been disease free for 4 months. Conclusions: GCT of bone with chondroid differentiation are well circumscribed, radiolucent tumors that arise in the epiphyseal and metaphyseal regions and are extremely uncommon. The differential diagnosis of this tumor includes chondroblastoma, osteoblastoma, giant-cell rich osteosarcoma, and other cartilage containing tumors. Further investigation is required to determine the exact nature of the chondroid matrix.
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STAT6 Immunohistochemistry Is Helpful in the Diagnosis of Solitary Fibrous Tumors
A Yoshida, K Tsuta, M Yoshida, R Kushima. National Cancer Center Hospital, Tokyo, Japan. Background: Solitary fi brous tumor (SFT) is an uncommon fi broblastic neoplasm. Although histological characteristics and frequent CD34 expression allow for an accurate diagnosis in the majority of SFT cases, a wide histological spectrum and an occasional unexpected immunophenotype may pose diagnostic challenges. Molecular analyses have discovered that almost all SFTs harbor a NAB2-STAT6 fusion gene, which is considered specifi c to this tumor type. Recent studies have suggested that STAT6 immunohistochemistry is a reliable surrogate for detection of the fusion gene. Our aim was to validate these fi ndings by examining a large number of SFT cases and a broad array of 30 different types of non-SFT tumors. Design: A total of 49 SFTs with a range of histological characteristics (including 33 conventional cases and 16 cases with unconventional histology) and 159 benign or malignant tumors that can mimic SFTs were retrieved. A representative block from each case was stained by using STAT6 antibody that recognizes the carboxy-terminal portion of this protein (polyclonal, sc-621, dilution 1:1000; Santa Cruz Biotechnology). The intensity of staining was semi-quantitatively graded as negative, weak, moderate, or strong. The extent of staining was classifi ed as negative (0 to < 5%), focal (5-50%), and diffuse (> 50 to 100%). Results: All 49 SFTs (100%) showed STAT6 expression that was restricted in the nucleus, irrespective of the tumor sites and histological patterns. The staining was diffuse in all but 1 case. The intensity was strong in 45 cases, moderate in 3 cases, and weak in 1 case. The staining was uniform in most cases, but was heterogeneous in about 20% of the cases where zonal staining attenuation was observed likely refl ecting variability in fi xation or tissue ischemia. In contrast, only 4 non-SFT tumors (2.5%) exhibited weak nuclear STAT6 expression, while the remaining 155 cases showed no staining (81 cases) or often weak reactivity in both the cytoplasm and the nucleus (74 cases). Conclusions: Nuclear STAT6 immunoreactivity, typically in a diffuse strong manner, is highly sensitive and specifi c for SFTs and is diagnostically helpful. This pattern of expression likely refl ects the NAB2-STAT6 fusion protein, and should be distinguished from the usually weak cytoplasmic/nuclear expression associated with full-length STAT6 that can be seen in some non-SFT tumors. STAT6 reactivity may depend on preanalytical conditions, and the quality of specimens and preparations needs to be carefully monitored if this technique is to be applied to routine diagnosis of SFTs.
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Differential SALL4 Immunoexpression in Epithelioid Sarcomas and Malignant Rhabdoid Tumors A Yoshida, N Asano, A Kawai, A Nakazawa, H Kishimoto, R Kushima. National Cancer Center Hospital, Tokyo, Japan; National Center for Child Health and Development, Tokyo, Japan; Saitama Children's Medican Center, Saitama, Japan. Background: Epithelioid sarcomas (ESs) and malignant rhabdoid tumors (MRTs) are distinctive malignant neoplasms with characteristic clinicopathologic features. However, these 2 tumors share some phenotypes such as epithelioid/rhabdoid cytology, expression of epithelial markers, and immunohistochemical loss of INI1. This differential can be particularly problematic when tumors with MRT-like histology present in adults, and ancillary diagnostic tools are needed to separate the 2 entities. CD34 expression is widely believed to favor the diagnosis of ES, but no formal comparative study has been performed. Two recent reports showing SALL4 expression in >80% of MRTs led us to evaluate the utility of this marker in differentiating ES and MRT. Design: Archived materials of ESs (N = 34) and MRTs (N = 13) were retrieved and all diagnoses were confi rmed. ESs were of distal (N = 19), proximal (N = 10), or hybrid (N = 5) type, and mainly occurred in adult patients (age range, 15-54 y; median, 32 y). MRTs occurred in the CNS (atypical teratoid/rhabdoid tumors, N = 4), kidney (N = 3), or other sites (N = 6), and were in infants and children (age range, 0-12 y; median, 1 y). All ESs and MRTs lacked INI1 reactivity, except for 1 MRT case that retained INI1 but lacked BRG1. In addition, 2 problematic cases were collected; these tumors occurred in adults and showed diffuse sheets of INI1-defi cient uniform small round cells associated with scattered rhabdoid forms. A representative slide from each case was stained using antibodies against SALL4 and CD34, and the reactivity was scored as positive when >1% of tumor cells were labeled. Results: Eight (62%) of 13 MRTs expressed SALL4, primarily in a focal manner (extent, <5-90%; median, 45%) with variable intensity. In contrast, only 1 (3%) distal variant of the 34 ES cases was SALL4 positive. CD34 staining was observed in 9 (69%) of 13 MRTs and 24 (70%) of 34 ESs. Both INI1-defi cient problematic small round cell tumors in adults expressed SALL4. Conclusions: Despite limited sensitivity and an often focal nature of reactivity, SALL4 expression can aid in distinguishing MRTs from ESs. Contrary to popular belief, CD34 was found to have no utility in making such distinctions. SALL4 expression in our 2 problematic cases may indicate that these tumors may be best classifi ed as MRTs arising in adults.
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CAMTA1 Immunostaining Is Not Useful in Differentiating Epithelioid Hemangioendothelioma from Its Potential Mimickers Z Yusifl i, K Kosemehmetoglu. Hacettepe University Faculty of Medicine, Ankara, Turkey. Background: Epithelioid hemangioendothelioma (EHE) is a rare member of vascular tumors of intermediate malignancy. CAMTA1 encodes a transcription factor in all multicellular organisms, conserved in Arabidopsis to humans and is known to be highly encountered in the memory related regions of the human brain. Recently, presence of t(1;3) translocation and WWTR1/CAMTA1 gene fusion, which enhances CAMTA1 expression, is found to be specifi c to EHE. In this study, we investigated the CAMTA1 immune expression profi le of EHE and its potential mimickers using a commercially available CAMTA1 antibody immunohistochemically. Design: Standard whole sections from the formalin fi xed, paraffi n embedded of 12 EHEs, 10 angiosarcomas, 9 epithelioid sarcomas, 8 malignant melanomas, 8 signet ring carcinomas, 7 lobular carcinomas of breast, 2 epithelioid mesotheliomas, 2 rhabdoid tumors and 12 micellaneous hemangiomas were immunostained for anti-CAMTA1 (ab64119, 1:200; Abcam) after pretreatment with citrate pH 6.0 for 20 minutes at 97 °C. using Leica Bond detection kit with DAB chromogen. Nuclear CAMTA1 expression was scored for its intensity (as weak, moderate and strong) and extent as 'negative' (<5% of cells positive), '+1' (5-25% of cells positive), '2+' (25-50% of cells positive) and '3+' (>50% of cells positive). Results: Over 2+ strong/moderate nuclear staining was seen in 63 out of 70 cases (90%): 83% of EHEs, 90% of angiosarcomas, 89% of epithelioid sarcomas, 100% of malignant melanomas, 75% of signet ring carcinomas, 100% of lobular carcinomas of breast, 100% of epithelioid mesotheliomas, 50% of rhabdoid tumors and 92% of hemangiomas. Besides neurons, CAMTA1 expression was also observed in squamous epithelium, skin adnexa, breast lobules, prostate glands, bile ducts, colonic mucosa and gastric pits whereas hepatocytes, trophoblasts, lung, thyroid, smooth and striated muscles and fi broblasts were negative. Conclusions: EHE, its potential morphological mimickers and other benign or malignant vascular tumors showed strong and diffuse CAMTA1 expression, nullifying the potential use of CAMTA1 immunohistochemical staining as an adjunct in the differential diagnosis of epithelioid EHE. CAMTA1 expression was observed throughout the body, especially epithelial compartments, including mucosae, mesothelium and endothelium.
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Giant Cell Tumor of Bone in Children and Adolescent -A Series of 43 Cases Y Zhang, TW Bauer, JB Wojcik, GP Nielsen, AE Rosenberg. Cleveland Clinic, Cleveland, OH; Massachusetts General Hospital, Boston, MA; University of Miami, Miami, FL. Background: Giant cell tumor of bone (GCT) is a benign, locally aggressive neoplasm, which most frequently involves the epiphyseal ends of long bones in skeletally mature individuals. It rarely arises in individuals younger than 18 years of age. The aim of this study is to examine the clinical and pathologic characteristics of giant cell tumor of bone in children and adolescents. Design: The study cohort was identifi ed from the authors consult fi les and from the surgical pathology fi les of the participating institutions. The clinical, radiological and pathological features of the tumors were analyzed. Results: 43 patients (26 females and 17 males, with median age 14.8 years, ranging from 8 to 18) were identifi ed. Pain was the most common symptom, followed by swelling and pathologic fracture. As in adults, most tumors arose in the ends of long bones, with the femur as the most common site (10), followed by the tibia (9). The tumors also often developed in the small bones of the hands and feet (8), and other sites included the vertebral body (4), pubic ramus (3), fi bula (3), sacrum (2), humerus (1), ulna (1), olecranon (1), and maxilla (1). Radiographically, GCT in long bones often manifested as an eccentric, lytic, circumscribed, expansile mass involving the epiphyseal-metaphyseal area. In the short or fl at bones, the tumor often completely replaced the underlying bone. On magnetic imaging studies the tumors were typically hypointense on T1 and hyperintense on T2 weighted images. Soft tissue components were common. Microscopically, most tumors had the classic features of GCT. Atypical features included vascular invasion, increased mitotic activity, and focal cytologic atypia. Patients were usually treated with curettage and bone grafting. Follow-up information available on 8 patients (22 months to 26 years, av. 10 yrs.) showed that they were all disease free after treatment. Three cases involving the pubic ramus showed the most aggressive features, and one of the cases underwent malignant transformation after multiple recurrences. Conclusions: While it is rare, GCT occurs in children and adolescents with a female predominance, and a predilection for the ends of major tubular bones (53.5%). In comparison to adults it affects the small bones of the hands and feet more frequently (18.6%). Curettage is the mainstay of therapy and patients usually have a good outcome.
